Cocoa polyphenols and inflammatory markers of cardiovascular disease by Khan, Nasiruddin et al.
 Nutrients 2014, 6, 844-880; doi:10.3390/nu6020844 
 
nutrients 
ISSN 2072-6643 
www.mdpi.com/journal/nutrients 
Review  
Cocoa Polyphenols and Inflammatory Markers of 
Cardiovascular Disease 
Nasiruddin Khan 1,2,†, Olha Khymenets 2,†,*, Mireia Urpí-Sardà 2, Sara Tulipani 2,3,  
Mar Garcia-Aloy 2, María Monagas 4, Ximena Mora-Cubillos 2, Rafael Llorach 2  
and Cristina Andres-Lacueva 2 
1 Biomarkers Research Program, Biochemistry Department, College of Science, King Saud 
University, P.O. Box 2455, King Abdullah road, Riyadh 11451, Saudi Arabia;  
E-Mail: nasiruddin2006@gmail.com 
2 Biomarkers and Nutritional & Food Metabolomics Research Group, Department of Nutrition and 
Food Science, XaRTA, INSA, Campus Torribera; INGENIO-CONSOLIDER Program,  
Fun-C-Food CSD2007-063, Ministry of Science and Innovation, Faculty of Pharmacy,  
University of Barcelona, Av Joan XXIII, s/n, Barcelona 08028, Spain;  
E-Mails: murpi@ub.edu (M.U.-S.); sara.tulipani@gmail.com (S.T.); margarcia@ub.edu (M.G.-A.); 
ximenamora@ub.edu (X.M.-C.); rafallorach@ub.edu (R.L.); candres@ub.edu (C.A.-L.) 
3 Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, Hospital Complex 
(Virgen de la Victoria), Campus de Teatinos s/n, University of Málaga, Malaga 29010, Spain 
4 Institute of Food Science Research (CIAL), CSIC-UAM. C/Nicolás Cabrera 9,  
Campus de Cantoblanco, Madrid 28049, Spain; E-Mail: m.monagas@csic.es 
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail:okhymenets@ub.edu;  
Tel.: +34-93-40-35-930; Fax: +34-93-40-35-931. 
Received: 29 November 2013; in revised form: 30 December 2013 / Accepted: 6 February 2014 /  
Published: 21 February 2014 
 
Abstract: Epidemiological studies have demonstrated the beneficial effect of plant-derived 
food intake in reducing the risk of cardiovascular disease (CVD). The potential bioactivity 
of cocoa and its polyphenolic components in modulating cardiovascular health is now 
being studied worldwide and continues to grow at a rapid pace. In fact, the high polyphenol 
content of cocoa is of particular interest from the nutritional and pharmacological 
viewpoints. Cocoa polyphenols are shown to possess a range of cardiovascular-protective 
properties, and can play a meaningful role through modulating different inflammatory 
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markers involved in atherosclerosis. Accumulated evidence on related anti-inflammatory 
effects of cocoa polyphenols is summarized in the present review. 
Keywords: cocoa polyphenols; bioavailability; inflammation; CVD 
 
1. Introduction 
Of an estimated 17.3 million deaths globally from all causes in 2008, cardiovascular disease (CVD) 
accounted for 30% [1]. The cardiovascular epidemic is rapidly advancing in the world. It has been 
projected that by 2030 nearly 23.6 million people will die from cardiovascular disorders [2,3]. 
However, the majority of these deaths caused by CVD are preventable [4,5]. Epidemiological and 
clinical studies have shown that lifestyle modifications such as nutrition and exercise are initial 
protective measures to reduce the risk of CVD [6–9]. The consumption of plant-derived food, such as 
whole grains, fruits, and vegetables, has been recognized as one of the principal preventive factors in 
the risk of all-cause and CVD mortality [10–12]. Moreover, the absolute quantity and frequency of 
fruit and vegetable intake have been associated with lower CVD risk and, therefore, with lower CVD 
mortality [13,14]. The mechanisms by which fruit and vegetables exert their protective effects are not 
entirely clear, but experimental and population studies [15,16] have indicated that plant polyphenols 
are principal mediators. Numerous scientific reports accumulated over recent decades suggest that 
plant polyphenols may exert their activities on the antioxidant system, signaling and transcription 
pathways, thus affecting principal mechanisms involved in cardiovascular events, such as systemic 
inflammation, lipid metabolism, hemostatic and vascular events, and immune response [17–23]. 
Cocoa products are among the richest sources of polyphenols in our diets. Nowadays cocoa has 
become a widely consumed food component, with growing demand across the world [24]. Interest in 
the biological activities of cocoa (Theobroma cacao) polyphenols has increased steadily, since the first 
studies on the positive link between plant food polyphenol consumption and health outcomes were 
reported. Cocoa has the highest flavanol content of all foods on a per-weight basis and is a significant 
contributor to the total dietary intake of flavonoids [25,26]. Depending upon geographical origins and 
plant varieties, the total polyphenol content of cocoa ranges from 40.0 mg GAE/g (GAE; gallic acid 
equivalent) to 84.2 mg GAE/g [27–30]. However, portions in chocolate, the most commonly consumed 
processed cocoa product, are significantly lower, with levels of 1.7–8.4 mg/g reported in dark 
chocolate and even lower levels of 0.7–5 mg/g in milk chocolate [31,32]. 
Several population studies have reported on the inverse association between cocoa intake (e.g., 
chocolate) and CVD mortality [33,34]. A number of recent meta-analyses of intervention studies have 
demonstrated that there is substantial evidence that cocoa consumption affects multiple cardiovascular 
risk factors such as blood pressure [35], insulin resistance [36], lipid profiles [37], and flow-mediated 
vascular dilatation (FMD) [38]. On the other hand, there are numerous in vitro and in vivo experimental 
data supporting the notion that polyphenols may mediate these beneficial effects of cocoa [39–41]. 
Nowadays, it has become more evident that inflammatory mediators play a key role in the 
pathology of atherosclerosis, starting from the initial phases of leukocyte recruitment, and finishing 
with the eventual rupture of the vulnerable atherosclerotic plaque [42–44]. Therefore, atherosclerosis 
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and cardiovascular pathologies caused by it are readily recognized and treated as inflammatory 
diseases [45]. Practically all cardiovascular risk factors are to a different extent linked to inflammation, 
while inflammation itself is recognized as a cardiovascular risk factor [46,47]. 
The participation of dietary polyphenols in the modulation of inflammation and how this could 
contribute to the reduction of cardiovascular risk was recently discussed [48]. There is a growing body 
of evidence on the anti-inflammatory activities of cocoa polyphenols. The protective role of cocoa  
in CVD inflammation has been considered in a number of human intervention studies, and numerous 
in vitro studies have also been carried out, led by an interest in disclosing the mechanisms and 
identifying the agents responsible for the anti-inflammatory cardio-protective activities of cocoa. 
Accordingly, polyphenols have been proposed as principal anti-inflammatory mediators. In this 
review, we aim to summarize these findings in order to assess the effects of cocoa polyphenols on 
cardiovascular-related inflammation. 
2. Cocoa Polyphenols 
Polyphenols in cocoa beans could contribute to about 12%–18% of the dry weight [49], making 
them practically inedible due to the bitterness and astringency [50]. Wollgast and Anklam [51] reported 
that catechins, anthocyanins, and proanthocyanidins constitute about 37%, 4% and 58% of cocoa bean 
polyphenols, respectively. Flavanols are the most important class of cocoa polyphenols [51,52]. They 
are presented by monomers ((+)- and (−)-isomers of catechin and epicatechin and their derivatives) 
and build-up of (epi)catechin subunit polymers (proanthocyanidins) [53]. Phenolic acids, flavonols  
and their glycosides, some stilbenes, simple phenols, and isocoumarins are also present in minor 
amounts [54–56]. Cyanidin-3-α-L-arabinoside and cyanidin-3-β-D-galactoside have been reported to be 
principal anthocyanins of cocoa, however, mainly in unprocessed fresh beans [51]. (−)-Epicatechin 
constitutes about 35% of the total phenolic content of cocoa beans, while other catechins, such as  
(+)-catechin, (+)-gallocatechin, and (−)-epigallocatechin, are present in smaller quantities. Dimers  
(B1, B2, B3, B4 and B5), trimers (C1), and oligomers (tetramer D) of flavan-3,4-diols, linked by 4→8 
or 4→6 bounds (B-type linkage), represent the main cocoa polymers, procyanidins [53,57,58]. The 
structures of the main cocoa polyphenols, monomeric and polymeric flavanols, are shown in Figure 1. 
Some other procyanidins have been identified in smaller amounts in fresh cocoa beans: dodecamer and 
three A-type (2→7 or 2→5 along with 4β→8 linkage) procyanidin dimmers [53,59] probably derive 
from oxidative conversion of B-type procyanidins [60,61]. In general, unfermented (fresh) cocoa beans 
contain flavanols with a varied range of polymerization, from monomers up to decamers [62]. 
The polyphenol content of cocoa could vary up to 4-fold depending on different varieties [63] and 
origins [64]. In addition to the above factors, cocoa beans undergo several steps of primary and 
secondary processing due to which the ratio and types of polyphenols found in cocoa beans are 
different from those found in the finished products [65]. For instance, the processes of fermentation 
and alkalization reduce the polyphenol content [63,66–68] and, consequently, the antioxidant activity 
of cocoa beans [32,67]. Thus, (−)-epicatechin and (+)-catechin decrease depending on the extent of 
cocoa bean fermentation: unfermented, partly fermented or fully fermented. In addition, high 
temperatures and long duration of processing also decrease the polyphenol content [51,68,69]. Some 
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special methodological adjustments could be applied in order to prevent cocoa polyphenols from 
oxidation during different stages of cocoa processing, increasing their content in a final product [70,71]. 
Figure 1. (I) Main cocoa flavanol monomers: (+)-catechin; (−)-epicatechin; (II) Main 
cocoa flavanol polymers: (a–e)—dimers: procyanidin B1, B2, B3, B4, B5, respectively;  
(f)—trimer: procyanidin C1; (g)—tetramer: procyanidin D. 
 
Semi-finished products such as cocoa liquor, and cocoa butter and cocoa powder derived from it, 
which are manufactured during secondary processing, are usually used in manufacturing final cocoa 
products (e.g., cocoa powder and chocolate) [72]. Sometimes unprocessed cocoa bean powder is 
introduced, mainly in order to enrich the polyphenol content of the final product [50,73]. The content 
of polyphenols in the final product is defined by the amount and type of cocoa components. Thus, 
cocoa powder is shown to have higher polyphenol content than cocoa butter [39,74], since it is mainly 
the low-fat solid component of cocoa nibs. Non-fat cocoa solids (NFCS) are considered to represent 
the total phenolic content in cocoa products [75]. Based on NFCS, cocoa powder represents the highest 
phenolic content (72%–87%), followed by baking chocolate (45%–49%), dark chocolate (20%–30%), 
semi-sweet chocolate (15%–19%), and milk chocolate (5%–7%) [76]. The quantitative determination 
of polyphenol content in a cocoa product can be assessed by using either total polyphenols [31] or the 
a b c 
e f g 
d 
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measurements of (−)-epicatechin and (+)-catechin [26], and also B-type procyanidin contents [73]. 
Based on weight in grams, (−)-epicatechin and (+)-catechin content follows a decreasing order, cocoa 
powder > dark chocolate > milk chocolate [77], while each content could be widely variable.  
For example, for cocoa powder it can range from 116.02 to 730.26 μg/g for (−)-epicatechin, and  
from 81.40 to 447.62 μg/g for (+)-catechin, the total monomeric content ranging from 182.84 to 
1066.13 μg/g [68]. In general, according to the polyphenol database Phenol-Explorer [78], the mean 
values of (−)-epicatechin and (+)-catechin are about 158 and 107, 70 and 20, and 15 and 5 mg/100 g 
FW in cocoa powder, dark chocolate, and milk chocolate, respectively. However, the amount of 
consumed cocoa polyphenols would also depend on serving size, thus, in a normal diet, dark chocolate 
would provide more polyphenols than other cocoa products [39]. 
As a consequence of whole processing, cocoa-derived products mainly contain less bioavailable  
(−)-catechin enantiomer, in contrast to cocoa beans and most foods that contain (+)-catechin [79,80]. 
Analyses of polyphenols have shown a relative abundance of oligomers and individual components  
in cocoa liquor, which follows the order: monomers > trimers > dimers > tetramers and  
epicatechin > procyanidin B2 > procyanidin C1 > catechin, respectively [81]. The trend in cocoa 
powder was different and followed the order: monomers > dimers > trimers > tetramers and 
epicatechin > catechin > procyanidin B2 > procyanidin C1, respectively [81]. Trace amounts of 
gallocatechin and epigallocatechin [55] and quercetin aglycone as well as some quercetin glycosides 
have been identified in cocoa liquor and cocoa powder [56,82]. Some additional flavonoids, such as 
naringenin, luteolin, apigenin and some glycosides of these compounds, and quercetin-glucuronide 
were also reported [68,77]. 
On the whole, during cocoa processing the polyphenol content is reduced more than ten  
times [74,83], with the undesirable bitter and astringent taste diminishing sometimes in final cocoa 
products. Cocoa food products existing on the market are characterized by highly diverse polyphenol 
content, mainly due to the differences in cocoa processing and product manufacturing, in addition to 
intrinsic geographical and genetic plant divergence [61,73,77,84]. Epidemiological and clinical studies 
on the health benefits of cocoa polyphenols should account for this variability in addition to other 
aspects, such as the bioavailability of putatively bioactive cocoa polyphenols, which we will discuss in 
the following section. 
3. Bioavailability of Cocoa Polyphenols 
In order to provide conclusive evidence for the effectiveness of cocoa polyphenols in disease 
prevention and human health improvement, it is essential to determine the nature and distribution of 
these compounds in our diet. In addition, the bioavailability of the ingested cocoa polyphenols will 
circumscribe organism exposure to these putatively bioactive compounds, affecting a magnitude of 
related health outcomes. There are a number of factors influencing the bioavailability of cocoa 
polyphenols, starting from their dietary consumption and finishing with their fate in the human organism. 
The daily consumption of cocoa catechins and procyanidins depends on cultural and regional 
dietary habits [75]. It has been estimated that in some regions (e.g., Belgium/Luxemburg) cocoa 
product consumption could reach up to 6 kg in cocoa beans/person per annum, the world average being 
0.55 kg/person per annum [85]. The majority of intervention and cross-sectional studies regarding the 
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health effects of cocoa have been conducted using cocoa beverages or chocolate as the most habitually 
used cocoa products [86], therefore bioavailability and intervention studies have also been focused 
mainly on these cocoa products. The protagonists of these studies are the major cocoa flavanols, 
epicatechin and procyanidins, since they have so far been foreseen as the principal bioactive  
cocoa polyphenols due to both their abundance and their relevance to biological activities and 
physicochemical structures [49,87,88]. 
Upon ingestion of cocoa products in doses close to habitual diet monomeric and polymeric cocoa 
flavanols are rapidly absorbed. Thus, it was shown that procyanidins and monomers could be detected 
in plasma as early as 0.5 h and maximal plasma concentration of these compounds was reached at 
about 2 h after ingestion [89–100]. The plasmatic Tmax of detected cocoa flavanols did not normally 
exceed 3 h, and their elimination from plasma in most cases was already achieved 6 h after cocoa 
consumption [94–96]. However, some epicatechin metabolites could have a delayed appearance and 
could remain in systemic circulation for up to 24 h, suggesting their intestinal microbiota catabolic 
origin [97,98]. Rapid plasmatic appearance suggests that the detected polyphenols are mainly absorbed 
in the small intestine. This was ratified by the data coming from in vitro and in vivo bioavailability 
studies on catechins and procyanidins [99,101,102]. However, absorption of flavan-3-ols in the small 
intestine is not complete, and depends not only on flavanol chemistry, but also on their structural 
isomerism and stereoisomerism [103]. Therefore, epicatechins and catechins were shown to have 
different levels of absorption [93,94], and plasma concentration of (+) and (−) forms of catechin were 
found to be different after cocoa product consumption [79,104]. The level of absorption, furthermore, 
depends on the range of polymerization, which will also limit their bioavailability [49]. In vitro studies 
suggested that flavanols only up to trimers were able to pass through the small intestine [101,102]. In 
humans, only traces of procyanidin B2 were detected in human plasma after ingestion of cocoa 
products [93,94]. More complex flavanols appeared to be stable under acidic conditions mimicking 
stomach digestion [105], so that, being unabsorbed in the small intestine, they are transited to the large 
intestine, where they are subjected to catabolic activities of intestinal microbiota [106]. 
Under absorption in the gastrointestinal tract, cocoa flavanols (monomers) are recognized by the 
organism as xenobiotics and are extensively transformed into various metabolites [107]. (−)-Epicatechin 
in its sulfate, glucuronides or methyl conjugated forms were the main forms representing about 33%, 
28%, and 33% of total epicatechin metabolites in human plasma and urine [97], the most  
relevant being (−)-epicatechin-3′-β-d-glucuronide, (−)-epicatechin 3′-sulfate, 3′-O-methyl-(−)-epicatechin 
sulfates [97,108]. In fact, epicatechin aglycone was undetectable both in plasma and urine according to 
recent findings, where advanced methods were applied [97,108]. 
Due to the gastrointestinal and hepatic metabolism, the conjugated metabolites are destined to be 
rapidly eliminated from the human body. Cocoa flavanols, absorbed in the small intestine, are 
normally cleared form the body over 24 h, like the majority of dietary polyphenols. On the other hand, 
a large proportion of unabsorbed flavanols, e.g., polymers and monomers, are subjected to colonic 
microflora catabolic activities [106,109,110]. Consequently, low-molecular-weight microbiota 
catabolites of these flavanols are absorbed from the colon, belatedly emerging in systemic circulation 
as phase II conjugates [106,107,111]. Valerolactones and valeric acids were reported to be first-step 
microbiota-derived catabolites [106,112] of unabsorbed small intestine epicatechin and  
procyanidins [112–115], whereas various phenolic acids were identified as intermediate and last-step 
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products of microbial flavanol catabolism [106,111,113,116]. On the other hand, a part of unabsorbed 
flavanols can accumulate in the low digestive tract and are finally excreted from the human body  
with faeces [106,117,118]. Plasmatic concentrations vary widely among reported flavanol  
microbiota metabolites, some of them reaching micromolar levels in response to cocoa polyphenol  
consumption [114]. The studies in human urine have not only indicated the bioavailability but  
also demonstrated the importance of the phase II conjugated metabolites and some colonic  
microbiota metabolites as promising biomarkers of cocoa consumption [119–121], justifying their 
application for dietary compliance control in cocoa intervention studies along with hydrolyzed 
epicatechin [114,122–124]. 
Recently, the scientific community has become aware that the microbe-derived metabolites of 
polyphenols represent a large proportion of dietary polyphenol intake [106,125–128], impacting on 
their bioavailability and potentially exhibiting some bioactive effects [129–132]. Moreover, regular 
consumption of polyphenol-rich cocoa could in turn influence the colonic bacterial population and 
metabolic activities [133], enlarging inter-individual flavanol bioavailability variation [134]. For 
example, a significant difference in bacterial metabolite profiles between regular cocoa product 
consumers and non-consumers was reported in response to dark chocolate intervention [135]. 
Nowadays, microbial cocoa metabolites are being reconsidered with regard to their health-related 
bioactivities, including those related to CVD inflammation, which we will address later in the 
corresponding section. 
The interaction between different nutrients, the food matrix and texture are one of several important 
factors that affect the bioavailability of cocoa polyphenols. The effect of milk, the most commonly 
used food element in cocoa-formulated products, on the bioavailability of both primary cocoa 
polyphenols and their host and microbiota metabolites has been studied with different cocoa  
products [96,113,136–140]. However, conclusions on this issue have remained controversial. In 
addition, carbohydrates and proteins [141–143], along with the complex food matrix and cocoa 
product physical stage (liquid vs. solid) [144,145], were also considered to interfere in the mechanism 
of flavanol uptake, affecting the bioaccessibility and bioavailability of cocoa polyphenols in  
human subjects. 
Although in the majority of the intervention studies the doses of cocoa products were close to high 
rather than average in habitual consumption, systemically circulating (plasmatic) concentrations of 
cocoa flavanols were reported to be relatively low—from nano- to micro-molar range for epicatechin 
and not always detected nano-molar concentrations for procyanidins [95,98,100,146]. Low maximum 
concentration (Cmax), a short half-life, extensive metabolic conjugation and rapid excretion, all add up 
to relatively low cocoa polyphenol bioavailability, compromising their relevance for health effects and 
bioactivities reported in in vitro and in vivo mechanistic studies [147]. On the other hand, there are data 
showing that sustained chronic consumption of cocoa products can lead to a relatively low but 
significant accumulation of cocoa polyphenols in human plasma [148], sufficient to exert some  
health-relevant bioactivity. These data support the idea that high doses of cocoa polyphenols might not 
always be needed to manifest biological activities, and the time of interaction could also be important. 
The absorption of cocoa polyphenols, characterized as epicatechin 24 h urinary recovery data, was 
considered to be poor, reaching not more than 30% of the total ingested (−)-epicatechin both with 
chocolate and with cocoa powder [97,98]. Some studies reported much lower recoveries [96,103], 
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especially when the cocoa polyphenol doses were closer to habitual dietary consumption and cocoa 
products were co-administrated with milk [96]. The participation of procyanidins in epicatechin 
bioavailability due to catabolic activities of colonic microflora is still being questioned due to the 
controversy in reported data [108,115]. Data on cocoa polyphenol absorption did not account for 
microbial-derived metabolites. So far, addressing this issue has proved challenging, since the majority 
of identified microbiota flavanol catabolites are not epicatechin specific and could also be related to 
other dietary polyphenols and/or unrelated microbial activities [106]. 
Although levels of circulating cocoa polyphenol metabolites appeared to be dose dependent [95,100], 
high inter-individual variability, mainly defined by individual metabolic phenotypes [149,150], was 
reported in practically all bioavailability studies. On the other hand, large inter-individual differences 
in colonic flavanol bioconversion, attributed to the individual colonic microbiota composition, are also 
expected to have an impact on variation in the bioavailability of cocoa polyphenols [127,134]. Such 
variability is difficult to control on the population level due to the nature of its matter; therefore, it still 
remains one of the main concerns in interventional studies regarding polyphenols’ health-benefiting 
activities, as it compromises the accurate estimation and correct interpretation of studied outcomes. 
4. Cocoa Polyphenols and CVD Inflammatory Markers 
Evidence from several epidemiological studies has demonstrated the favorable association of cocoa 
and its derived products with a lower risk of CVD mortality [33,40,151]. Thus, the effect of high cocoa 
consumption in Kuna Indians who lived in their indigenous islands in Panama has been related to 
lower blood pressure and low mortality rates as compared to Kunas emigrated to the urban areas of 
Panama City, revealing its favorable effect [152]. In the Dutch Zutphen Study, in a cohort of elderly 
men, high cocoa intake was related to lower blood pressure and was inversely associated with 
cardiovascular and all-cause mortality [33]. In Women’s Health Study, chocolate intake was also 
found to be inversely associated with cardiovascular mortality, along with other foods rich in 
flavonoids, such as some fruits and red wine [153]. 
Although the mechanism for the beneficial effects of cocoa and its derived products still remains to 
be fully elucidated, the potential biological role of flavanols has been suggested by various  
human interventions [36,38–40] and in vitro/in vivo mechanistic studies [39–41]. So far, among the 
most relevant impacts of cocoa polyphenols on cardiovascular health should be highlighted their  
effect on the most significant markers of CVD: oxLDL [124,154,155], lipid profile [124,154,156], 
blood pressure [35,157,158], nitric oxide [52,159], hemostasis [91,148,160] and endothelial 
dysfunction [159,161,162]. 
Thus, it is well known that alteration in plasma cholesterol levels (LDL-c and HDL-c) is related to 
the progression of atherosclerosis and CVD [163]. Dietary medium-term intervention with cocoa 
powder in mild hypercholesterolemic subjects showed significantly lower levels of LDL-c [164], while 
the level of HDL-c was found to be increased in normo- and mild hyper-cholesterolemic subjects after 
dark chocolate or cocoa powder consumption [154,164,165]. A recent study in women affected by 
normal weight obese syndrome, which is characterized by a higher risk of cardiovascular morbidity 
and mortality, suggested that regular consumption of dark chocolate had favorable effects on HDL-c, 
lipoprotein ratios and inflammation markers [166]. Oxidized LDLs play a crucial role in the 
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progression of atherosclerosis [167]. There are several studies that have established oxidized low-density 
lipoprotein (oxLDL) as a useful marker for cardiovascular diseases [168–171]. Cocoa polyphenols 
have been shown to decrease the oxidation of LDL in in vitro studies [172,173]. In addition, 
intervention studies have demonstrated that isolated LDLs are less prone to in vitro oxidation after  
the consumption of various cocoa products [154,155,174–176]. Moreover, a recent study including  
42 high-risk human subjects reported a significant decrease in plasma oxLDL levels in addition to a 
significant increase in plasma HDL-c concentration after chronic cocoa consumption [124]. The role of 
cocoa polyphenols has also been investigated for their effect on vascular systems, which could lead to 
reduced risk of CVD. The main targets include nitric oxide (NO) concentration and endothelial 
function, along with decreased susceptibility of LDL to oxidation and inhibition of platelet activation 
and aggregation [155,177,178]. In numerous studies, which were recently reviewed [179], both acute 
and sustained consumption of flavanol-containing cocoa products were reported to have a dose-dependent 
beneficial effect on endothelial function via an improvement in FMD. An increase in the plasma nitric 
oxide (NO) concentration has been shown in healthy subjects after the consumption of cocoa beverages 
containing different contents of flavanols. This change in plasma NO-modulated FMD indicates an 
association between increased bioavailability of NO and improved endothelial function [180]. Cocoa 
polyphenols from dietary sources may also improve endothelial functions by augmenting  
NO-synthase activity [52,159,181,182], leading to a decrease in systolic and diastolic blood  
pressure [162,183,184]. Platelet aggregation occurs during the initiation of coronary thrombosis and 
several studies support evidence about the potent activity of cocoa polyphenols as inhibitors of platelet 
aggregation and adhesion, thus reducing clot formation [185,186]. 
Cardiovascular pathology is accompanied by chronic low-intensity inflammation, involving the 
participation of a variety of cells (endothelial, smooth muscular, monocytes, lymphocytes and 
platelets), adhesion molecules (selectins, integrins and immunoglobulin superfamily molecules), 
cytokines (pro-inflammatory and anti-inflammatory), chemokines, growth factors and enzymes 
(metalloproteases, cyclooxygenases and lipoxygenases) [187]. These inflammatory mediators appear 
to play a key role in each step of atherogenesis, starting from the initial phases of leukocyte 
recruitment, to the eventual rupture of the vulnerable atherosclerotic plaque [44]. Some of these key 
players are often used in the evaluation of a grade of pathological changes or response to treatment, 
usually referring to them as CVD-related inflammatory markers [188]. Apart from this, inflammation 
itself is considered a risk factor for CVD [187,189,190]. Therefore, circulating levels of the 
inflammatory markers could also reflect the current inflammatory state of the individuals, exhibiting 
their risk status in respect of CVD. The accumulated evidence on the health benefits of cocoa for 
disorders of a chronic inflammatory nature, such as CVD, prompted the need to focus on the 
association between bioactive cocoa polyphenols and inflammatory mediators of CVD, with the 
purpose of identifying and recognizing factors involved and mechanisms underlying this interaction. 
4.1. Human Studies 
Up until now, only one epidemiologic study has reported on the relationship between cocoa 
consumption and inflammation. Thus, a large cohort study involving men and women randomly 
recruited from the general population demonstrated a J-shaped relationship between dark chocolate 
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consumption and serum hs-CRP, a CVD inflammatory marker. Those subjects who usually consumed 
up to 1 serving (20 g) of dark chocolate every 3 days had significantly lower serum hs-CRP 
concentrations than non-consumers [191]. Most of the evidence on the possible interaction between 
cocoa polyphenols and CVD-related inflammation was obtained in clinical intervention studies 
involving human subjects. The human intervention studies evaluating the effect of cocoa polyphenols 
on inflammatory mediators of CVD are presented in Table 1. 
As well as the above-mentioned epidemiological study, CRP (C-reactive protein), a biomarker 
strongly associated with coronary heart disease and inflammation [192], was evaluated in several 
clinical trials with cocoa (Table 1). However, only a few of these studies reported on changes in CRP 
levels due to cocoa consumption. Thus, one of the first intervention trials performed by Mathur [176] 
and Kurlandsky [193] reported no changes in hs-CRP circulation in healthy subjects due to medium-term 
intervention with dark chocolate. However, a decrease in the CRP systemic levels of healthy subjects 
was observed after short- and medium-term daily consumption of cocoa beverages in two recent 
studies [194,195]. The decrease in circulating CRP was shown to be linear in response to the 
polyphenol content of the consumed cocoa beverages, according to the data from the latest study [195]. 
It is worth noting that both studies had crossover designs with well-matched treatment controls 
(adjusted for other important cocoa bioactive compounds, such as theobromine and caffeine), which 
reinforce the evidence on the role of cocoa polyphenols in this interaction. A short-term intervention 
study reported on specific gender changes in hs-CRP upon dark chocolate consumption observed in 
healthy female but not male volunteers [196]. However, these findings should be confirmed in a 
bigger, controlled matched intervention on a well-recruited female population to avoid any impact of 
hormonal status during the menstrual cycle on systemic inflammation [197]. In contrast to crossover 
studies on healthy subjects, no impact of cocoa consumption was observed on the hs-CRP level in 
subjects with compromised cardiovascular health in the few available studies [123,198,199]. Thus, in a 
medium-term crossover study with hypertensive pre-diabetic subjects, dark chocolate consumption 
was compared to white chocolate with an impact on certain CVD markers, including circulating levels 
of CRP. Although authors reported a beneficial effect of medium-term consumption of dark chocolate 
on vascular function, insulin sensitivity, and BP in hypertensive patients, no effects were observed on 
the hs-CRP level [199]. No change in hs-CRP levels was detected either in subjects at high 
cardiovascular risk in another crossover study after chronic cocoa powder in milk intake [123]. A 
parallel arm intervention study [198], involving patients with coronary artery disease, reports that over 
a 6-week period, flavanol-rich cocoa does not modify vascular function in patients with established 
CAD. Along with vascular functions evaluated postprandially (90 min) and after chronic consumption 
(3 and 6 weeks), circulating hs-CRP was evaluated. However, it was not affected either by acute or 
chronic consumption of cocoa-derived products. 
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Table 1. Human intervention studies considering the relationship between cocoa polyphenols and cardiovascular disease (CVD)-related 
inflammatory markers (studies are presented in chronological order). Ref. = Reference. 
Intervention 
Comparison 
Population Markers of 
Dietary 
Compliance 
Cocoa Consumption Impact Ref. 
Cocoa Source (dose) 
Type 
(time) 
Study 
Design 
Polyphenol Content N Subjects Status 
High- vs. Low-
procyanidin chocolate  
(37 g/dose) 
AI CO 
High-procyanidin 
chocolate: 148 mg tot. Pr 
Low-procyanidin 
chocolate: 3.3 mg tot. Pr
H vs. L 10 Healthy 
2 h plasma (BM) 
6 h plasma (BM)
2 h postprandial: 
↓leukotriene/prostacyclin ratio  
↓leukotrienes (C4 + D4 + E4) 
↑prostacyclins 
[89] 
Dark chocolate +  
cocoa beverage  
(36.9 g + 30.95 g/day) 
MTI  
(6 weeks) 
NC 
Chocolate (daily):  
168.3 mg Pr  
Cocoa beverage (daily): 
483.1 mg Pr 
Before/After 25 Healthy 
Plasma  
(tot. PPh) 
No effect: IL-1beta, IL-6, TNF-α, 
hs-CRP, P-selectin 
[176] 
Dark chocolate  
(41 g/day) 
MTI  
(6 weeks) 
PA NA 
Before/After 
DC vs. Ctrl 
group 
10 Healthy NA 
↓ICAM-1  
No effect: VCAM-1 and hs-CRP 
[193] 
Chocolate and cocoa 
beverage (48 g chocolate 
+ 18 g cocoa 
beverage/day) 
AI  
(90 min) 
MTI  
(6 weeks) 
PA  
PA 
Flavanol group (daily): 
444 mg flavanols  
107 mg epicatechin  
Control group (daily):  
19.6 mg flavanols  
4.7 mg epicatechin 
Before/After 
Flavanol vs. 
Placebo (Ctrl)
40
Coronary artery disease 
(CAD) 
NA 
No effect (acute or chronic):  
ICAM-1, VCAM-1, E- and  
P-selectins and hs-CRP 
[198] 
Low- and High-flavanol 
cocoa beverages  
(36 g powder (18.8 g 
cocoa) per 240 mL W) 
MTI  
(6 weeks) 
PA 
High-flavanol group:  
446 mg tot. flavanols  
Low-flavanol group:  
43 mg tot. flavanols 
Before/After 
H vs. L group 
32
Postmenopausal 
hypercholesterolemic 
women 
Fasting plasma 
(BM) 
↓sVCAM-1(High-flavanol group) 
No effect: ICAM-1; E- and  
P-selectins 
[200] 
Dark chocolate 70%  
(100 g/day) 
STI  
(7 days) 
NC Daily: 700 mg flavonoids Before/After 28 Healthy NA 
↓hs-CRP (females only, n = 19)  
No effect: hs-CRP (common 
group) 
[196] 
  
Nutrients 2014, 6 855 
 
 
Table 1. Cont. 
Dark chocolate  
(50 g/day × 2 times/day)
MTI  
(15 days) 
CO 
Dark chocolate (daily):  
1008 mg tot. PPh  
110.9 mg epicatechin  
36.12 mg catechin  
White chocolate(daily):  
0.13 g tot. PPh  
0.04 mg catechin 
DC vs. WC (Ctrl) 19
Hypertensive 
prediabetic 
NA No effects: hs-CRP [199] 
Cocoa beverage  
(31 g/150 mL W ×  
2 times/day 
MTI  
(2 weeks) 
CO 
Flavanol beverage (daily):  
451 mg tot. PPh  
57 mg epicatechin  
31 mg catechin  
338 mg Pr  
Control beverage (daily):  
14 mg tot. PPh  
1 mg epicatechin  
4 mg catechin  
8 mg Pr 
Before/After  
Flavanol vs. Control 
beverage (Ctrl) 
20 Hypertensive 
Fasting plasma 
(BM) 
No effect: TNF-α, IL-6, MCP-1,  
E-selectin, VCAM-1, and ICAM-1 
[201] 
Cocoa powder  
(20 g/250 mL M ×  
2 times/day) 
MTI  
(4 weeks) 
CO 
Daily: 40.41 mg (+)-catechin 
46.08 mg (−)-epicatechin  
36.54 mg procyanidin B2  
495.2 mg tot.PPh  
425.7 mg tot.Pr 
Cocoa (CM) vs.  
M (Ctrl) 
42 CVD high risk 
24 h urine 
(BM) 
↓VLA-4, CD40, CD36 (monocytes)  
↓P-selectin and ICAM-1 (serum)  
Non-significant changes: ↓VCAM-1 
and MCP-1  
No effect: hs-CRP, IL-6, E-selectin 
[123] 
High- and Low-cocoa 
flavanol beverage (NA)
MTI  
(4 weeks) 
CO 
High-cocoa flavanol (daily): 
494 mg tot. Flavanols  
Low-cocoa flavanol (daily):  
23 mg tot. flavanols 
Before/After  
H vs. L 
20 Healthy 
Fasting plasma 
(BM)  
24 h urine 
(BM) 
↓CRP (High-cocoa flavanol group) [194] 
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Table 1. Cont. 
Different flavanol 
content cocoa beverages 
vs. Control beverage  
(28 g cocoa powder in 
W × 2 times/day) 
STI  
(5 days) 
CO 
Cocoa beverages (daily):  
180 mg flavanols (Low)  
400 mg flavanols (Medium)  
900 mg flavanols (High)  
Control beverage (daily):  
30 mg flavanols 
L, M, H vs. Control 
beverage (Ctrl) 
20 Obese healthy NA 
↓CRP  
↓IL-6  
No effect: ICAM 
[195] 
Dark chocolate 70%  
(25 g ×2 times/day) 
MTI  
(4 weeks) 
NC 
Daily:  
2135 mg PPh 
Before/After 20
Hypertensive (excess 
body weight) 
NA 
Non-significant changes:  
↓ICAM-1  
↓VCAM-1,  
↓E-selectin 
[202] 
Dark chocolate 70%  
(100  g/day) 
STI  
(7 days) 
NC 
444 mg/kg catechin  
908 mg/kg epicatechin 
Before/After 15
Normal weight obese 
women 
NA 
↓IL-1Ra and  
No effect: IL-1α, IL-1β, IL-6, and 
TNF-α 
[166] 
Cocoa product rich in 
fibre(15 g/200 mL M × 
2 times/day) 
MTI  
(4 weeks) 
CO 13·9 mg/g soluble PPh Cocoa vs. M (Ctrl)
24 
20
Healthy and 
Hypercholesterolemic 
subjects 
NA 
↓IL-1β, IL-10  
No effect: IL-6, TNF-α, IL-8,  
MCP-1, VCAM and ICAM 
[156] 
Cocoa powder  
(40 g/250 mL M or W)
AI (6 h) CO 
Daily: 40.41 mg (+)-catechin 
46.08 mg (−)-epicatechin  
36.54 mg procyanidin B2  
495.2 mg tot.PPh  
425.7 mg tot.Pr 
Before/After  
Cocoa (CM+CW) 
vs. W (Ctrl)  
CM vs. CW 
18 Healthy 
2 h plasma 
(BM)  
6 h urine (BM)
↓NF-κB  
↓E-selectin  
↓ICAM-1  
No effect: VCAM-1 
[203] 
AI—acute intervention; BM—biomarkers for dietary compliance (e.g., phase II epicatechin metabolites and/or total epicatechin or total flavanols); C—cocoa; CO—crossover design; CRP—C-reactive protein;  
hs-CRP—high sensitivity C-reactive protein; Ctrl—control; DC—dark chocolate; ICAM-1, Intercellular Adhesion Molecule-1; IL-6, Interleukin-6; M—Milk; MCP-1—Monocyte Chemoattractant Protein-1; 
MTI—medium-term intervention; NC—no control design; PA—parallel arm design; PPh—polyphenols; STI—short-term intervention; VCAM-1—Vascular Cell Adhesion Molecule-1; VLA-4—Very Late 
Activation Antigen-4; W—water; WC—white chocolate. 
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The differences in the circulating levels of cell adhesion molecules may reveal a stage for 
pathophysiological events due to activation or damage to various cells [204–206]. Some studies with 
solid designs (crossover and parallel arm), involving both healthy and unhealthy subjects, were not 
able to detect cocoa intake-provoked changes in the circulation of key adhesion molecules such as 
ICAM-1 and VCAM-1 [156,195,198,201]. However, some other studies reported a positive impact of 
cocoa consumption on the different types of CVD inflammation-related adhesion molecules. Thus, in  
a group of postmenopausal hypercholesterolemic women consuming a high-flavanol cocoa beverage 
(446 mg of total flavanols), there was a 2.4-fold increase in hyperemic blood flow associated with  
a significant decrease in plasma levels of VCAM-1, compared to the low-flavanol cocoa beverage 
group (43 mg of total flavanols). However, no differences were seen for E- and P-selectins, along with 
ICAM-1 [200]. On the other hand, no significant changes were observed for VCAM-1, but circulating 
ICAM-1 concentrations significantly decreased after consumption of dark chocolate (41 g/day) by 
healthy subjects [193]. A study performed by Monagas and colleagues suggests that the chronic 
consumption of cocoa powder may modulate the expression of adhesion molecules (soluble and 
expressed on T-cell and monocyte surfaces) related to the early stages of atherosclerosis in subjects at 
high risk of coronary heart disease. In a randomized crossover medium-term feeding trial they 
demonstrated a lower serum concentration of P-selectin and ICAM-1 and decreased expression of cell 
adhesion molecules (very late activation antigen-4 (VLA-4), CD40, and CD36) on the monocyte 
surface after intervention with cocoa powder in skimmed milk (C + M) vs. only skimmed milk 
ingestion (M). The circulating levels of VCAM-1 and MCP-1 concentrations were also lower, but not 
statistically significant, while that of E-selectin remained unchanged after C+M compared with M 
intake [123]. Their results agreed with the previously reported decrease in ICAM-1 in healthy 
volunteers due to chronic dark chocolate consumption [193]. However, for the first time a positive 
effect of cocoa consumption on P-selectin concentrations was reported by Monagas and colleagues, in 
contrast to previous results obtained on both healthy [176] and health-compromised subjects [198,200]. 
Nuclear factor κB (NF-κB) is a key molecule in the pathophysiology of atherosclerosis involved in 
the regulation of adhesion molecules and cytokine expression [207]. A recent crossover study on 
healthy subjects evaluated the effect of acute cocoa consumption in different matrices related to  
the bioavailability of cocoa polyphenols in NF-κB activation and the expression of adhesion  
molecules [203]. The administration of 40 g of cocoa powder either with milk (CM) or water (CW) 
decreased ICAM concentration 6 h after intake, while E-selectin levels were lower only after CW 
intervention, with no changes in VCAM-1 concentration either with CM or CW interventions. Acute 
consumption of cocoa with water (CW) significantly decreased NF-κB activation in peripheral blood 
monocytes compared to baseline and to CM [203], whereas milk treatment alone (control) significantly 
induced NF-κB activation. On the other hand, cocoa mixed with milk had no effects on NF-κB 
activation. The observed differences were attribute to the different bioavailability of polyphenolic 
compounds present in cocoa powder when taken with milk or water, which was monitored during  
the study as urinary host phase II (epicatechin-Glucs and -Sulfs) and microbial (sum of the  
3,4-dihydroxyphenylacetic, protocatechuic, 4-hydroxybenzoic, 4-hydroxyhippuric, hippuric, caffeic 
and ferulic acids) metabolites [203]. Therefore, it was suggested that cocoa consumption could confer 
beneficial anti-inflammatory effects mediated by inhibition of the NF-κB-dependent transcription 
pathway or interaction with certain cytokines and the food matrix can modulate this effect. 
Nutrients 2014, 6 858 
 
 
Interleukins are thought to be involved in the chronic inflammatory response that is typical of 
atherosclerosis [206]. A one-week regular consumption of dark chocolate (100 g/day) in normal 
weight obese women showed a significant reduction in the serum level of the interleukin-1 receptor 
antagonist (IL-1Ra) and its positive correlation with total cholesterol, LDL cholesterol and CVD risk 
indexes changes. A neutral effect on other pro-inflammatory cytokine (IL-1α, IL-1β, IL-6, and TNF-α) 
and hs-CRP levels was reported [166]. Similar results were obtained for inflammatory markers 
including TNF-α, IL-1β, IL-6 and P-selectin along with hs-CRP in a non-controlled clinical trial, 
which failed to find any changes in interleukins in healthy subjects upon consumption of  
polyphenol-rich cocoa supplements, consisting of dark chocolate (36.9 g/day) and cocoa powder 
(30.95 g/day) for 6 weeks [176]. However, a recent crossover study [156] on normo- and  
hyper-cholesterolemic subjects demonstrated the decreased serum level of IL-1β and IL-10 after 
regular 4-week consumption of cocoa products with milk (15 g twice per day) as compared to control 
(milk). Other measured parameters such as IL-6, TNF-α, IL-8, MCP-1, and vascular and intracellular 
cell adhesion molecule levels remained unchanged [156]. 
Recently, leukotrienes (LTs) have been implicated as mediators, biomarkers, and possible 
therapeutic targets in the context of subclinical atherosclerosis [208]. Leukotrienes are arachidonic acid 
(AA)-derived lipid mediators of inflammation, exerting a range of pro-inflammatory effects, and have 
proved to be important mediators in inflammatory conditions such as preclinical atherosclerosis. For 
this reason, it has been suggested that leukotriene synthesis inhibitors and leukotriene receptor 
antagonists induce beneficial effects at preclinical stages of the atherosclerotic process [209]. Data 
from an early short-term crossover intervention study suggest that cocoa polyphenols can favourably 
alter eicosanoid synthesis in humans, providing a plausible hypothesis for a mechanism by which they 
can decrease platelet activation in humans [89]. Thus, the consumption of high-procyanidin chocolate 
resulted in increased prostacyclin and decreased leukotriene concentrations, and, as result, in a 
decreased leukotriene-prostacyclin ratio, a measure of the pro-inflammatory/anti-inflammatory 
eicosanoid balance [89]. 
Although the majority of human studies provide evidence for a possible interaction between cocoa 
polyphenols and inflammatory mediators involved in CVD, practically all of them warn about certain 
limitations and appeal for further, better designed intervention studies to confirm the presented 
outcomes. Overall, in order to determine the biological effect of cocoa polyphenols and to reach any 
beneficial conclusion that could possibly be implemented in human health, large-scale randomized 
placebo-controlled studies are required to confirm and expand upon the potential anti-inflammatory 
role of polyphenol-rich cocoa products. Moreover, the design of human intervention trials should use  
a relevant amount of cocoa products, which corresponds to real-life doses and could readily be 
incorporated into the regular human diet. 
4.2. Animal Models, in Vitro and Cell Culture Studies 
There are not many in vivo animal studies specifically focused on the CVD-related activity of cocoa 
polyphenols, and even fewer considering inflammatory mediators [41]. However, as demonstrated by 
human studies, animal intervention studies also support the capability of cocoa polyphenols to 
effectively suppress the production of cytokines and adhesion molecules that promote CVD-related 
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inflammation. In a recent study by Gu and colleagues [210], male mice previously fed with a high-fat 
(HF) diet for 8 weeks were randomized to a HF diet or HF diet supplemented with 8% cocoa powder 
(HF–HFC group) for 10 weeks. Cocoa supplementation significantly decreased the plasma levels of 
the pro-inflammatory mediators, IL-6 (30.4%) and the expression of several pro-inflammatory  
genes (Il6, Il12b, Nos2, and Emr1) in mice. Moreover, unlike the study reported by Monagas and 
colleagues [123] in humans, the above study also demonstrated a significant decrease in MCP-1, after 
cocoa supplementation.  
It is noteworthy that the composition of chocolate or cocoa differing in polyphenol contents and 
dietary doses could lead to different outcomes in CVD risk end points [211,212]. Most of the human 
intervention studies using chocolate or cocoa powder supplementation have reported a protective effect 
related to systemic inflammation. On the other hand, a recent study by Yakala et al. [213] demonstrated 
the unfavorable effect of chocolate consumption on cardiovascular parameters. In this study, the 
effects of chocolate supplementation were studied in ApoE*3-Leiden mice, a model susceptible to 
diet-induced atherosclerosis, fed with a high-cholesterol control diet supplemented with two different 
chocolates (A and B), where chocolate A had a relatively high-polyphenol and low-fibre content 
compared to chocolate B. After both chocolate treatments, an increase in plasma cholesterol and 
atherosclerotic plaque formation was observed, compared to the mice fed only with a high-cholesterol 
diet. In addition, mice on a high-cholesterol diet supplemented with chocolate B showed elevated 
plasma levels of VCAM-1 and E-selectin, whereas the chocolate A showed no effects. 
Supplementation with chocolate A appeared to be less unfavorable than chocolate B with respect to 
inflammatory parameters, which was related to the higher circulating polyphenol concentrations 
present in the A group. Therefore, the discrepancies reported in this study were attributed to the 
difference in the polyphenol composition of chocolate and quantity consumed. In contrast to the 
chocolate intervention, a recent study reported that a 7-day high-cocoa diet (4.8 g/kg/day) reduced the 
production of pro-inflammatory cytokines (IL-6 and TNF-α), along with the production of NO and 
reactive oxygen species, in rat peritoneal macrophages ex vivo [214]. However, no significant changes 
were found in this study when a lower (2.4 g/kg/day) cocoa diet was applied. 
In comparison to animal models, in vitro and cell culture models were more extensively applied in 
research on the CVD anti-inflammatory properties of cocoa polyphenols. 
Table 2 represents the studies regarding the effects of cocoa polyphenols on inflammatory 
mediators discussed previously for human intervention studies. The in vitro and cell culture 
experiments were originally appointed to help identify cellular and molecular targets for the  
anti-inflammatory activities of cocoa polyphenols. 
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Table 2. In vitro studies on cocoa polyphenol CVD-related anti-inflammatory activities. Ref. = Reference. 
Model Treatment (dose) Outcomes Ref. 
Leukotrienes 
(a) Isolated rabbit 15-LOX-1  
(b) Recombinant human platelet 12-LOX
(a) Cocoa procyanidins: monomers to 
decamers (2.9 mg/mL)  
(b) Epicatechin & procyanidin decamers 
Dose-dependent: (a) ↓15-LOX-1 activity  
(b) ↓12-LOX activity [215] 
Recombinant human 5-LOX 
Cocoa epicatechin & procyanidins  
(10 μmol/L) 
↓5-LOX activity  
↓Pro-inflammatory mediators (LTB4, LTC4, LTD4) [216] 
Pro-Inflammatory and Anti-Inflammatory Cytokines 
PHA-stimulated PBMC 
Cocoa procyanidins: monomers through 
decamers (25 μg/mL) 
↓IL-1β secretion (monomer to tetramer)  
↑IL-1β secretion (pentamer to decamer)  
↓IL-2 expression (pentamer to heptamer)  
↓IL-4 expression & secretion (pentamer to decamer) 
[217] 
Human PBMC 
Cocoa procyanidins: monomers through 
decamers (25 μg/mL) 
↑IL-1β transcription & secretion (pentamers-decamers) 
↓IL-1β transcription & secretion (monomers-tetramers) [218] 
Resting and (PHA)-stimulated human 
PBMC 
Cocoa procyanidins: monomers through 
decamers (25 μg/mL) 
Resting PBMCs:  
↑IL-4 secretion (hexamer-decamer fraction)  
PHA-stimulated PBMCs:  
↑IL-4 secretion (monomeric fraction)  
↓IL-4 secretion (hexamer-decamer fraction) 
[219] 
Resting and (PHA)-stimulated human 
PBMC 
CFP fractions: monomers through 
decamers (25 μg/mL) 
↓ TNF-α (monomers and dimers)  
↑ TNF-α (tetramers through octamers) [220] 
PHA-stimulated PBMC 
Cocoa flavanols and their related 
oligomers (25 μg/mL) 
↓ IL-5 release (oligomeric fractions: hexamers to 
decamers) 
[221] 
Rat NR8383 macrophages 
Cocoa polyphenol extract (10–50 μg/mL 
tot. PPh) vs. epicatechin (30–60 μg/mL 
tot. PPh) 
↓ TNF-α, MCP-1, IL-1α, IL-6) [222] 
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Table 2. Cont. 
Pro-Inflammatory and Anti-Inflammatory Cytokines 
Murine EL4BOU6 lymphocytes 
Cocoa extract (5–80 μg/mL tot. PPh) vs. 
epicatechin (60–120 μg/mL tot. PPh) 
↓IL-2 secretion  
↑IL-4 secretion  
↓T lymphocyte activation 
[223] 
Human PBMC 
Cocoa flavanol fractions: Short  
(monomers-pentamers)  
Long-chain (hexamers-decamers) (20 μg/mL) 
↑IL-1β, IL-6, IL-10, TNF-α (long-chain fraction) [224] 
LPS-stimulated human PBMC 
Cocoa phenolic acids: (3,4-DHPPA, 3-HPA,  
3,4-DHPAA, 3-HPAA,  
4-HBA) (1 µM) 
↓TNF-α  
↓IL-6  
↑IL-1β 
[225] 
NF-κB Activity 
Jurkat T cells 
Purified cocoa: [(−)-epicatechin (EC) and  
(+)-catechin (CT)] and a B dimeric procyanidin 
(DP-B) (1.7–17.2 µM) 
↓NF-κB  
↓IL-2 transactivation [226] 
4-DHPAA—3,4-dihydroxyphenylacetic acid; 3,4-DHPPA—3,4 dihydroxyphenylpropionic acid; 3-HPA—3-hydroxyphenylpropionic acid; 3-HPAA—3-hydroxyphenylacetic 
acid; 4-HBA—4-hydroxybenzoic acid; CFP—Cocoa flavanols preparation; LOX—lipoxygenase; MCP-1—monocyte chemoattractant protein-1; PBMC—peripheral 
blood mononuclear cells; PHA—phytohemagglutinin; VSMC—vascular smooth muscle cells. 
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It has been shown that cocoa polyphenols can inhibit lipoxigenase activity in vitro [215,216]. 
Inflammatory mediators, leukotrienes, are formed via the 5-lipoxygenase pathway of arachidonic  
acid metabolism; therefore, cocoa polyphenols might modulate leukotrienes via eicosanoid  
metabolism [180]. Schewe and colleagues [215,216] reported that cocoa (−)-epicatechin and its  
low-molecular procyanidins inhibit both dioxygenase and LTA(4) synthase activities of human  
5-LOX, the first two consecutive steps in the conversion of arachidonic acid into leukotrienes. 
Moreover, epicatechin and procyanidin decamer inhibited the recombinant human platelet 12-LOX. 
They suggested that this mechanism may underlie a putative anti-inflammatory effect of cocoa 
products. Thus, their outcomes are in line with the results from the in vivo study, where healthy 
subjects had lower levels of the plasma leukotrienes LTC4, LTD4 and LTE4, along with increased 
levels of prostacyclin, 2 h after procyanidin-rich chocolate consumption [89]. 
Intervention studies suggest that dietary cocoa polyphenols may modulate atherogenic 
inflammatory processes via interaction with cytokines. Several in vitro studies have studied the 
immunomodulatory effects of cocoa polyphenols on the production of cytokines in human peripheral 
blood mononuclear cells (Table 2). Thus, studies performed by Mao and colleagues [217–221] 
demonstrated that some fraction of cocoa polyphenols may exhibit anti-inflammatory activities by 
modulating the production of pro-inflammatory cytokines, including IL-1β, IL-2, IL-6 and TNF-α, and 
secretion of the anti-inflammatory cytokine IL-4 [219]. The nature and extent of this modulation were 
strongly dependent on the degree of polymerization of the tested procyanidins. Thus, smaller fractions 
of cocoa polyphenols (monomers-tetramers) consistently decreased pro-inflammatory IL-1b 
expression, while the larger oligomers (pentamers-decamers) increased its expression [218]. Ramiro 
and colleagues also reported that cocoa extract and epicatechin mediated a decrease in the secretion 
and RNA expression of various pro-inflammatory mediators by macrophages, such as MCP-1, TNF-α, 
IL-1α, and IL-6 mRNA expressions, suggesting that a cocoa polyphenol inhibitory effect on cytokine 
secretion is produced, in part, at the transcriptional level [222]. However, a striking increase in the 
LPS-induced synthesis of IL-1β, IL-6, IL-10, and TNF-α in the presence of long-chain flavanols from 
cocoa by mononuclear cells was demonstrated in another in vitro study [224]. Epicatechin and cocoa 
extract were also shown to significantly reduce IL-2Rα (CD25) expression and IL-2 secretion on 
activate peripheral blood mononuclear cells [223]. In resting and PHA-stimulated PBMC, the 
intermediate-sized cocoa flavanol and procyanidin fractions (tetramers to octamers) were shown to 
display an increase in TNF-α secretion. The monomers and dimers were slightly inhibitory, while 
trimers, nonamers and decamers induced TNF-α levels [220]. Cocoa flavanols and their related oligomers 
were also able to modulate IL-5 in PHA-stimulated peripheral blood mononuclear cells [221].  
A study reported the effect of cocoa microbial-derived phenolic acids (3,4 dihydroxyphenylpropionic 
acid (3,4-DHPPA), 3-hydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid (3,4-DHPAA),  
3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid and 4-hydroxyhippuric acid (4-HHA)) on  
the modulation of the production of pro-inflammatory cytokines, i.e., TNF-α, IL-1β and IL-6, in  
LPS-stimulated PBMC [225]. The phenolic acids used were at a biological concentration level (1 mM) 
within the range (0.1–10 mM) found in plasma samples after cocoa polyphenol intake [227]. Only the 
dihydroxylated compounds, 3,4-DHPPA and 3,4-DHPAA, with the exception of 4-HHA for TNF-α 
secretion, significantly inhibited the secretion of these pro-inflammatory cytokines. The concentrations 
of IL-6 were reduced with 3,4-DHPPA and 3,4-DHPAA pretreatment. This study demonstrated that 
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dihydroxylated phenolic acids derived from colonic microbial metabolites could probably act as an 
anti-inflammatory agent, providing favourable effects on CVD [225]. 
NF-κB is a redox-sensitive transcription factor that regulates the expression of large family of genes, 
including those encoding proteins involved in inflammation such as IL-1, IL-6, and TNF-α [228]. 
Flavanols have been shown to modulate the inflammatory effect in cultured RAW264.7 murine 
macrophages via NF-κB pathways, and this depended on the degree of polymerization [229]. Thus, 
monomers and dimers repressed the TNF-α secretion and NF-κB-dependent gene expression induced 
by interferon γ, whereas the procyanidin C2 enhanced them. Epicatechin monomers were also shown 
to interact with NF-κB and inhibit TNF-α-stimulated activation of T lymphocytes [226]. Epicatechin 
and procyanidins can inhibit NF-κB at different levels in the activation pathways, where the decrease 
in cell oxidants that are involved in NF-κB activation and the prevention of NF-κB activation via 
specific interaction with signaling proteins are seen as main mechanisms [230]. On the whole, the 
results from these studies demonstrate that cocoa polyphenols can act as modulators of the immune 
response in immune cells involved in the early stages of atherogenic inflammation. 
Although only a few studies have been carried out, animal experiments are expected to contribute 
much to the mechanistic understanding of the role of cocoa polyphenols in CVD inflammatory 
processes. However, these models have certain limitations that should be considered while interpreting 
results and extrapolating them to humans: type and dose for intervention, model vs. human-specific 
metabolism, etc. Regarding in vitro and cell culture studies, the main concern is the type of cocoa 
polyphenols applied for treatment. Since in CVD-related inflammatory research models usually 
represent the processes normally occurring close to systemic circulation (immune cells, vascular and 
endothelial tissues), the main compounds considered in these interactions should be bioavailable 
metabolites of polyphenols, mainly presented as phase II host and microbial metabolites of 
epicatechin. In addition, it is difficult to make an alignment between doses of polyphenols tested in  
in vitro models and those normally related to dietary consumption in humans. 
5. Conclusions 
The data from clinical and experimental studies considered in this review suggest that cocoa 
products, due to its high polyphenol content, may exert anti-inflammatory properties. Yet much 
remains to be elucidated on the interaction of cocoa polyphenols with inflammatory mediators 
involved in cardiovascular pathology. Larger, well-designed, placebo-controlled studies are expected 
to approach this question. At this point, there is a certain need to address recently raised new aspects 
regarding cocoa polyphenol bioavailability in future investigations. One of them is the role of cocoa 
polyphenol metabolites in respect of their anti-inflammatory properties. Cocoa polyphenol 
bioavailability depends on numerous varying components, which are sometimes difficult to control in 
clinical and population studies. To get a better approximation of the association between cocoa 
polyphenol consumption and its health outcomes, a detailed monitoring of cocoa polyphenol 
bioavailability during intervention studies is required. Two main groups of metabolites should be 
considered, both in human and in model studies: host and microbiota-derived metabolites. Recent 
human studies have already started to account for these metabolites, not only as dietary compliance 
biomarkers, but also to assess their impact on human health [156,166,202,203,210,214]. This is also 
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supported by the fact that polyphenol microbial metabolites can exert various biological activities, 
some of them with anti-inflammatory potential [106,123,225]. The role of phase II conjugation is 
another issue to be considered, especially in mechanistic studies on cocoa polyphenol bioactivities, 
e.g., their anti-inflammatory properties. Both host and microbial metabolites are mainly present as 
phase II conjugates in systemic circulation upon dietary intake of cocoa products. Therefore, they are 
principal forms of cocoa polyphenols available for targeting the inflammatory process in vivo. Being 
distinct from core compounds in their properties, these metabolites warrant being considered as 
principal mediators in cocoa CVD-related anti-inflammatory activities. On the other hand, a possible 
intracellular deconjugation metabolism of phase II metabolites, as was recently reported in a case with 
resveratrol [231], should also be considered and investigated in detail for cocoa polyphenols. 
Acknowledgments 
The authors are grateful for the support granted by the following Spanish government programmes: 
CICYT AGL2009-13906-C02-01, AGL2010-10084-E and FUN-C Food CSD2007-063 from the 
Ingenio-CONSOLIDER programme of the Spanish Government. The postdoctoral contract fellowship, 
awarded by the Ministry of Innovation and Science to Olha Khymenets and Sara Tulipani (Juan de la 
Cierva Program), and the predoctoral fellowships awarded by the Generalitat de Catalunya (FI-DRG) 
to Ximena Mora-Cubillos and Mar Garcia-Aloy are acknowledged. Mireia Urpí-Sardà and Rafael 
Llorach would like to thank Ramon y Cajal Program of the Spanish Ministry (MINECO) and the 
Fondo Social Europeo. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Global Status Report on Noncommunicable Diseases 2010; World Health Organization: Geneva, 
Switzerland, 2011. 
2. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; de Simone, G.;  
Ferguson, T.B.; Ford, E.; Furie, K.; Gillespie, C.; et al. Heart disease and stroke statistics—2010 
update: A report from the American Heart Association. Circulation 2010, 121, e46–e215. 
3. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 
2030. PLoS Med. 2006, 3, e442. 
4. Halfon, N.; Hochstein, M. Life course health development: An integrated framework for 
developing health, policy, and research. Milbank Q. 2002, 80, 433–479. 
5. Ben-Shlomo, Y.; Kuh, D. A life course approach to chronic disease epidemiology: Conceptual 
models, empirical challenges and interdisciplinary perspectives. Int. J. Epidemiol. 2002, 31,  
285–293. 
6. Wang, D.; He, Y.; Li, Y.; Luan, D.; Zhai, F.; Yang, X.; Ma, G. Joint association of dietary 
pattern and physical activity level with cardiovascular disease risk factors among Chinese men: 
A cross-sectional study. PLoS One 2013, 8, e66210. 
Nutrients 2014, 6 865 
 
 
7. Chomistek, A.K.; Manson, J.E.; Stefanick, M.L.; Lu, B.; Sands-Lincoln, M.; Going, S.B.; 
Garcia, L.; Allison, M.A.; Sims, S.T.; LaMonte, M.J.; et al. Relationship of sedentary behavior 
and physical activity to incident cardiovascular disease: Results from the Women’s Health 
Initiative. J. Am. Coll. Cardiol. 2013, 61, 2346–2354. 
8. Chomistek, A.K.; Cook, N.R.; Flint, A.J.; Rimm, E.B. Vigorous-intensity leisure-time physical 
activity and risk of major chronic disease in men. Med. Sci. Sports Exerc. 2012, 44, 1898–1905. 
9. Salehi-Abargouei, A.; Maghsoudi, Z.; Shirani, F.; Azadbakht, L. Effects of Dietary Approaches 
to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-incidence:  
A systematic review and meta-analysis on observational prospective studies. Nutrition 2013, 29, 
611–618. 
10. He, M.; van Dam, R.M.; Rimm, E.; Hu, F.B.; Qi, L. Whole-grain, cereal fiber, bran, and germ 
intake and the risks of all-cause and cardiovascular disease-specific mortality among women 
with type 2 diabetes mellitus. Circulation 2010, 121, 2162–2168. 
11. De Moura, F.F.; Lewis, K.D.; Falk, M.C. Applying the FDA definition of whole grains to the 
evidence for cardiovascular disease health claims. J. Nutr. 2009, 139, 2220S–2226S. 
12. Nettleton, J.A.; Steffen, L.M.; Loehr, L.R.; Rosamond, W.D.; Folsom, A.R. Incident heart failure 
is associated with lower whole-grain intake and greater high-fat dairy and egg intake in the 
Atherosclerosis Risk in Communities (ARIC) study. J. Am. Diet. Assoc. 2008, 108, 1881–1887. 
13. Dauchet, L.; Ferrieres, J.; Arveiler, D.; Yarnell, J.W.; Gey, F.; Ducimetiere, P.; Ruidavets, J.B.; 
Haas, B.; Evans, A.; Bingham, A.; et al. Frequency of fruit and vegetable consumption and 
coronary heart disease in France and Northern Ireland: The PRIME study. Br. J. Nutr. 2004, 92, 
963–972. 
14. Dauchet, L.; Montaye, M.; Ruidavets, J.B.; Arveiler, D.; Kee, F.; Bingham, A.; Ferrieres, J.; 
Haas, B.; Evans, A.; Ducimetiere, P.; et al. Association between the frequency of fruit and 
vegetable consumption and cardiovascular disease in male smokers and non-smokers. Eur. J. 
Clin. Nutr. 2010, 64, 578–586. 
15. Scalbert, A.; Johnson, I.T.; Saltmarsh, M. Polyphenols: Antioxidants and beyond. Am. J.  
Clin. Nutr. 2005, 81, 215S–217S. 
16. Arts, I.C.; Hollman, P.C. Polyphenols and disease risk in epidemiologic studies. Am. J.  
Clin. Nutr. 2005, 81, 317S–325S. 
17. Bhupathiraju, S.N.; Tucker, K.L. Greater variety in fruit and vegetable intake is associated with 
lower inflammation in Puerto Rican adults. Am. J. Clin. Nutr. 2011, 93, 37–46. 
18. Clifton, P.M. Effect of grape seed extract and quercetin on cardiovascular and endothelial 
parameters in high-risk subjects. J. Biomed. Biotechnol. 2004, 2004, 272–278. 
19. Aviram, M.; Rosenblat, M.; Gaitini, D.; Nitecki, S.; Hoffman, A.; Dornfeld, L.; Volkova, N.; 
Presser, D.; Attias, J.; Liker, H.; et al. Pomegranate juice consumption for 3 years by patients 
with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and 
LDL oxidation. Clin. Nutr. 2004, 23, 423–433. 
20. George, T.W.; Niwat, C.; Waroonphan, S.; Gordon, M.H.; Lovegrove, J.A. Effects of chronic 
and acute consumption of fruit- and vegetable-puree-based drinks on vasodilation, risk factors for 
CVD and the response as a result of the eNOS G298T polymorphism. Proc. Nutr. Soc. 2009, 68, 
148–161. 
Nutrients 2014, 6 866 
 
 
21. Duthie, S.J.; Jenkinson, A.M.; Crozier, A.; Mullen, W.; Pirie, L.; Kyle, J.; Yap, L.S.; Christen, P.; 
Duthie, G.G. The effects of cranberry juice consumption on antioxidant status and biomarkers 
relating to heart disease and cancer in healthy human volunteers. Eur. J. Nutr. 2006, 45, 113–122. 
22. Franke, A.A.; Cooney, R.V.; Henning, S.M.; Custer, L.J. Bioavailability and antioxidant effects 
of orange juice components in humans. J. Agric. Food Chem. 2005, 53, 5170–5178. 
23. Naruszewicz, M.; Laniewska, I.; Millo, B.; Dluzniewski, M. Combination therapy of statin with 
flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers 
in patients after myocardial infraction (MI). Atherosclerosis 2007, 194, e179–e184. 
24. Source: UNCTAD Based on the Data from International Cocoa Organization, Quaterly Bulletin 
of Cocoa Statistics). Available online: http://www.unctad.info/en/Infocomm/Beverages/Cocoa2/ 
Market/ (accessed on 10 August 2013). 
25. Lee, K.W.; Kim, Y.J.; Lee, H.J.; Lee, C.Y. Cocoa has more phenolic phytochemicals and a 
higher antioxidant capacity than teas and red wine. J. Agric. Food Chem. 2003, 51, 7292–7295. 
26. Vinson, J.A.; Proch, J.; Zubik, L. Phenol antioxidant quantity and quality in foods: Cocoa, dark 
chocolate, and milk chocolate. J. Agric. Food Chem. 1999, 47, 4821–4824. 
27. Lea, A.G.H. The Procyanidins of Cocoa. In Proceedings of the American Chemical Society 
Meeting, Denver, CO, USA, 5–10 April 1987. 
28. Lea, A.G.H.; Ford, G.D. The Polyphenols of Cocoa Part I: Isolation and Characterisation of 
Procyanidins from Unfermented Beans; The Cadbury Schweppes Group: London, UK, 1988. 
29. Lea, P.J.; Ford, G.D. Characterisation of the Polyphenols of Cocoa; Bioflavour: Glasgow,  
UK, 1990. 
30. Niemenak, N.; Rohsius, C.; Elwers, S.; Ndoumou, D.O.; Lieberei, R. Comaparative study of 
different cocoa (Theobroma cacao L.) clones in terms of their phenolics and anthocyanins 
contents. J. Food Compos. Anal. 2006, 19, 612–619. 
31. Waterhouse, A.L.; Shirley, J.R.; Donovan, J.L. Antioxidants in chocolate. Lancet 1996, 348, 834. 
32. Adamson, G.E.; Lazarus, S.A.; Mitchell, A.E.; Prior, R.L.; Cao, G.; Jacobs, P.H.; Kremers, B.G.; 
Hammerstone, J.F.; Rucker, R.B.; Ritter, K.A.; et al. HPLC method for the quantification of 
procyanidins in cocoa and chocolate samples and correlation to total antioxidant capacity.  
J. Agric. Food Chem. 1999, 47, 4184–4188. 
33. Buijsse, B.; Feskens, E.J.; Kok, F.J.; Kromhout, D. Cocoa intake, blood pressure, and 
cardiovascular mortality: The Zutphen Elderly Study. Arch. Intern. Med. 2006, 166, 411–417. 
34. Janszky, I.; Mukamal, K.J.; Ljung, R.; Ahnve, S.; Ahlbom, A.; Hallqvist, J. Chocolate 
consumption and mortality following a first acute myocardial infarction: The Stockholm Heart 
Epidemiology Program. J. Intern. Med. 2009, 266, 248–257. 
35. Ried, K.; Sullivan, T.R.; Fakler, P.; Frank, O.R.; Stocks, N.P. Effect of cocoa on blood pressure. 
Cochrane Database Syst. Rev. 2012, 8, CD008893. 
36. Hooper, L.; Kay, C.; Abdelhamid, A.; Kroon, P.A.; Cohn, J.S.; Rimm, E.B.; Cassidy, A. Effects 
of chocolate, cocoa, and flavan-3-ols on cardiovascular health: A systematic review and  
meta-analysis of randomized trials. Am. J. Clin. Nutr. 2012, 95, 740–751. 
37. Jia, L.; Liu, X.; Bai, Y.Y.; Li, S.H.; Sun, K.; He, C.; Hui, R. Short-term effect of cocoa product 
consumption on lipid profile: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 
2010, 92, 218–225. 
Nutrients 2014, 6 867 
 
 
38. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; le Cornu, K.A.; Ryder, J.J.;  
Hall, W.L.; Cassidy, A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis 
of randomized controlled trials. Am. J. Clin. Nutr. 2008, 88, 38–50. 
39. Visioli, F.; Bernaert, H.; Corti, R.; Ferri, C.; Heptinstall, S.; Molinari, E.; Poli, A.; Serafini, M.; 
Smit, H.J.; Vinson, J.A.; et al. Chocolate, lifestyle, and health. Crit. Rev. Food Sci. Nutr. 2009, 
49, 299–312. 
40. Corti, R.; Flammer, A.J.; Hollenberg, N.K.; Luscher, T.F. Cocoa and cardiovascular health. 
Circulation 2009, 119, 1433–1441. 
41. Rimbach, G.; Melchin, M.; Moehring, J.; Wagner, A.E. Polyphenols from cocoa and vascular 
health—A critical review. Int. J. Mol. Sci. 2009, 10, 4290–4309. 
42. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2045–2051. 
43. Packard, R.R.; Libby, P. Inflammation in atherosclerosis: From vascular biology to biomarker 
discovery and risk prediction. Clin. Chem. 2008, 54, 24–38. 
44. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868–874. 
45. Hansson, G.K. Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost. 2009,  
7, 328–331. 
46. Willerson, J.T.; Ridker, P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 
109, II2–II10. 
47. Kaplan, R.C.; Frishman, W.H. Systemic inflammation as a cardiovascular disease risk factor and 
as a potential target for drug therapy. Heart Dis. 2001, 3, 326–332. 
48. Tangney, C.C.; Rasmussen, H.E. Polyphenols, inflammation, and cardiovascular disease.  
Curr. Atheroscler. Rep. 2013, 15, 324. 
49. Bravo, L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. 
Nutr. Rev. 1998, 56, 317–333. 
50. Harwood, M.L.; Ziegler, G.R.; Hayes, J.E. Tolerance for high flavanol cocoa powder in 
semisweet chocolate. Nutrients 2013, 5, 2258–2267. 
51. Wollgast, J.; Anklam, E. Review on polyphenols in theobroma cacao: Changes in composition 
during the manufacture of chocolate and methodology for identification and quantification.  
Food Res. Int. 2000, 33, 423–447. 
52. Schroeter, H.; Heiss, C.; Balzer, J.; Kleinbongard, P.; Keen, C.L.; Hollenberg, N.K.; Sies, H.; 
Kwik-Uribe, C.; Schmitz, H.H.; Kelm, M. (−)-Epicatechin mediates beneficial effects of 
flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. USA 2006, 103,  
1024–1029. 
53. Porter, L.J.; Ma, Z.; Chan, B.G. Cacao procyanidins: Major flavonoids and identification of some 
minor metabolites. Phytochemistry 1991, 30, 1657–1663. 
54. Hurst, W.J.; Glinski, J.A.; Miller, K.B.; Apgar, J.; Davey, M.H.; Stuart, D.A. Survey of the  
trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products. J. Agric. 
Food Chem. 2008, 56, 8374–8378. 
55. Lamuela-Raventos, R.M.; Andres-Lacueva, C.; Permanyer, J.; Izquierdo-Pulido, M. More 
antioxidants in cocoa. J. Nutr. 2001, 131, 834–835. 
  
Nutrients 2014, 6 868 
 
 
56. Sanchez-Rabaneda, F.; Jauregui, O.; Casals, I.; Andres-Lacueva, C.; Izquierdo-Pulido, M.; 
Lamuela-Raventos, R.M. Liquid chromatographic/electrospray ionization tandem mass spectrometric 
study of the phenolic composition of cocoa (Theobroma cacao). J. Mass Spectrom. 2003, 38,  
35–42. 
57. Qin, Y.Z.; Holt, R.R.; Lazarus, S.A.; Ensunsa, J.L.; Hammerstone, J.F.; Schmitz, H.H.; Keen, C.L. 
Stability of flavan-3-ols epicatechin and catechin and related dimeric procyanidins derived from 
cocoa. J. Agric. Food Chem. 2002, 50, 1700–1705. 
58. Santos-Buelga, C.; Scalbert, A. Proanthocyanidins and tannin-like compounds—Nature, occurrence, 
dietary intake and effects on nutrition and health. J. Sci. Food Agric. 2000, 80, 1094–1117. 
59. Hammerstone, J.F.; Lazarus, S.A.; Mitchell, A.E.; Rucker, R.; Schmitz, H.H. Identification of 
procyanidins in cocoa (Theobroma cacao) and chocolate using high-performance liquid 
chromatography/mass spectrometry. J. Agric. Food Chem. 1999, 47, 490–496. 
60. Tanaka, T.; Kondou, K.; Kouno, I. Oxidation and epimerization of epigallocatechin in banana 
fruits. Phytochemistry 2000, 53, 311–316. 
61. Zhu, Q.Y.; Hammerstone, J.F.; Lazarus, S.A.; Schmitz, H.H.; Keen, C.L. Stabilizing effect of 
ascorbic acid on flavan-3-ols and dimeric procyanidins from cocoa. J. Agric. Food Chem. 2003, 
51, 828–833. 
62. Kelm, M.A.; Johnson, J.C.; Robbins, R.J.; Hammerstone, J.F.; Schmitz, H.H. High-performance 
liquid chromatography separation and purification of cacao (Theobroma cacao L.) procyanidins 
according to degree of polymerization using a diol stationary phase. J. Agric. Food Chem. 2006, 
54, 1571–1576. 
63. Clapperton, J.; Lockwood, R.; Romanczyk, L.; Hammerstone, J.F. Contribution of genotype to 
cocoa (Theobroma cacao L.) flavour. Trop. Agric. 1994, 71, 303–308. 
64. Azizah, O.; Amin, I.; Nawalyah, A.G.; Ilham, A. Antioxidant capacity and phenolic content of 
cocoa beans. Food Chem. 2007, 100, 1523–1530. 
65. Cooper, K.A.; Campos-Gimenez, E.; Jimenez Alvarez, D.; Nagy, K.; Donovan, J.L.; Williamson, G. 
Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa 
polyphenols and inter-relationships of their concentrations in chocolate. J. Agric. Food Chem. 
2007, 55, 2841–2847. 
66. Kim, H.; Keeney, P.G. (−)-Epicatechin content in fermented and unfermented cocoa beans.  
J. Food Sci. 1984, 49, 1090–1092. 
67. Robinson, T.; Ranalli, A.W.; Phillips, A.W. Changes in cocoa tannins during processing.  
J. Agric. Food Chem. 1961, 9, 295–298. 
68. Andres-Lacueva, C.; Monagas, M.; Khan, N.; Izquierdo-Pulido, M.; Urpi-Sarda, M.; Permanyer, J.; 
Lamuela-Raventos, R.M. Flavanol and flavonol contents of cocoa powder products: Influence of 
the manufacturing process. J. Agric. Food Chem. 2008, 56, 3111–3117. 
69. Kyi, T.M.; Wan Ramli, W.D.; Abu Bakar, M.; Mohd. Wahid, S.; Abdul Amir, H.K.;  
Meor Zainal, M.T. The kinetics of polyphenol degradation during the drying of malaysian cocoa 
beans. Int. J. Food Sci. Technol. 2005, 40, 323–331. 
70. Payne, M.J.; Hurst, W.J.; Miller, K.B.; Rank, C.; Stuart, D.A. Impact of fermentation, drying, 
roasting, and Dutch processing on epicatechin and catechin content of cacao beans and cocoa 
ingredients. J. Agric. Food Chem. 2010, 58, 10518–10527. 
Nutrients 2014, 6 869 
 
 
71. Hurst, W.J.; Krake, S.H.; Bergmeier, S.C.; Payne, M.J.; Miller, K.B.; Stuart, D.A. Impact of 
fermentation, drying, roasting and Dutch processing on flavan-3-ol stereochemistry in cacao 
beans and cocoa ingredients. Chem. Cent. J. 2011, 5, 53. 
72. Hii, C.L.; Law, C.L.; Suzannah, S.; Misnawi; Cloke, M. Polyphenols in cocoa (Theobroma 
cacao L.). Asian J. Food Agro Ind. 2009, 2, 702–722. 
73. Gu, L.; House, S.E.; Wu, X.; Ou, B.; Prior, R.L. Procyanidin and catechin contents and antioxidant 
capacity of cocoa and chocolate products. J. Agric. Food Chem. 2006, 54, 4057–4061. 
74. De Brito, E.S.; Garcia, N.H.P.; Gallao, M.I.; Cortelazzo, A.L.; Fevereiro, P.S.; Braga, M.R. 
Structural and chemical changes in cocoa (Theobroma Cacao) during fermentation, drying and 
roasting. J. Sci. Food Agric. 2000, 81, 281–288. 
75. Cooper, K.A.; Donovan, J.L.; Waterhouse, A.L.; Williamson, G. Cocoa and health: A decade of 
research. Br. J. Nutr. 2008, 99, 1–11. 
76. Miller, K.B.; Stuart, D.A.; Smith, N.L.; Lee, C.Y.; McHale, N.L.; Flanagan, J.A.; Ou, B.;  
Hurst, W.J. Antioxidant activity and polyphenol and procyanidin contents of selected 
commercially available cocoa-containing and chocolate products in the United States. J. Agric. 
Food Chem. 2006, 54, 4062–4068. 
77. Miller, K.B.; Hurst, W.J.; Flannigan, N.; Ou, B.; Lee, C.Y.; Smith, N.; Stuart, D.A. Survey of 
commercially available chocolate- and cocoa-containing products in the United States. 2. 
Comparison of flavan-3-ol content with nonfat cocoa solids, total polyphenols, and percent 
cacao. J. Agric. Food Chem. 2009, 57, 9169–9180. 
78. Neveu, V.; Perez-Jimenez, J.; Vos, F.; Crespy, V.; du Chaffaut, L.; Mennen, L.; Knox, C.; 
Eisner, R.; Cruz, J.; Wishart, D.; et al. Phenol-Explorer: An online comprehensive database on 
polyphenol contents in foods. Database 2010, 2010, bap024. 
79. Donovan, J.L.; Crespy, V.; Oliveira, M.; Cooper, K.A.; Gibson, B.B.; Williamson, G. (+)-Catechin 
is more bioavailable than (−)-catechin: Relevance to the bioavailability of catechin from cocoa. 
Free Radic. Res. 2006, 40, 1029–1034.  
80. Kofink, M.; Papagiannopoulos, M.; Galensa, R. (−)-Catechin in cocoa and chocolate: Occurrence 
and analysis of an atypical flavan-3-ol enantiomer. Molecules 2007, 12, 1274–1288. 
81. Natsume, M.; Osakabe, N.; Yamagishi, M.; Takizawa, T.; Nakamura, T.; Miyatake, H.; Hatano, T.; 
Yoshida, T. Analyses of polyphenols in cacao liquor, cocoa, and chocolate by normal-phase and 
reversed-phase HPLC. Biosci. Biotechnol. Biochem. 2000, 64, 2581–2587. 
82. Andrés-Lacueva, C.; Lamuela-Raventós, R.M.; Jáuregui, O.; Casals, I.; Izquierdo-Pulido, M.; 
Permanyer, J. An LC method for the analysis of cocoa phenolics. LC GC Eur. 2000, 12, 902–904. 
83. Bonvehi, J.S.; Coll, F.V. Evaluation of the bitterness and astringency of polyphenolic comppunds 
in cocoa powder. Food Chem. 1997, 60, 365–370. 
84. Stahl, L.; Miller, K.B.; Apgar, J.; Sweigart, D.S.; Stuart, D.A.; McHale, N.; Ou, B.; Kondo, M.; 
Hurst, W.J. Preservation of cocoa antioxidant activity, total polyphenols, flavan-3-ols, and 
procyanidin content in foods prepared with cocoa powder. J. Food Sci. 2009, 74, C456–C461. 
85. Emmanuel Ohene Afoakwa. Chocolate Science and Technology; Wiley-Blackwell: Hoboken, 
NJ, USA, 2010. 
Nutrients 2014, 6 870 
 
 
86. Arranz, S.; Valderas-Martinez, P.; Chiva-Blanch, G.; Casas, R.; Urpi-Sarda, M.;  
Lamuela-Raventos, R.M.; Estruch, R. Cardioprotective effects of cocoa: Clinical evidence from 
randomized clinical intervention trials in humans. Mol. Nutr. Food Res. 2013, 57, 936–947. 
87. Heim, K.E.; Tagliaferro, A.R.; Bobilya, D.J. Flavonoid antioxidants: Chemistry, metabolism and 
structure-activity relationships. J. Nutr. Biochem. 2002, 13, 572–584. 
88. Corcoran, M.P.; McKay, D.L.; Blumberg, J.B. Flavonoid basics: Chemistry, sources, mechanisms 
of action, and safety. J. Nutr. Gerontol. Geriatr. 2012, 31, 176–189. 
89. Schramm, D.D.; Wang, J.F.; Holt, R.R.; Ensunsa, J.L.; Gonsalves, J.L.; Lazarus, S.A.; Schmitz, H.H.; 
German, J.B.; Keen, C.L. Chocolate procyanidins decrease the leukotriene-prostacyclin ratio in 
humans and human aortic endothelial cells. Am. J. Clin. Nutr. 2001, 73, 36–40. 
90. Rein, D.; Lotito, S.; Holt, R.R.; Keen, C.L.; Schmitz, H.H.; Fraga, C.G. Epicatechin in human 
plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status.  
J. Nutr. 2000, 130, 2109S–2114S. 
91. Holt, R.R.; Schramm, D.D.; Keen, C.L.; Lazarus, S.A.; Schmitz, H.H. Chocolate consumption 
and platelet function. JAMA 2002, 287, 2212–2213. 
92. Pearson, D.A.; Paglieroni, T.G.; Rein, D.; Wun, T.; Schramm, D.D.; Wang, J.F.; Holt, R.R.; 
Gosselin, R.; Schmitz, H.H.; Keen, C.L. The effects of flavanol-rich cocoa and aspirin on ex vivo 
platelet function. Thromb Res. 2002, 106, 191–197. 
93. Steinberg, F.M.; Holt, R.R.; Schmitz, H.H.; Keen, C.L. Cocoa procyanidin chain length does  
not determine ability to protect LDL from oxidation when monomer units are controlled.  
J. Nutr. Biochem. 2002, 13, 645–652. 
94. Holt, R.R.; Lazarus, S.A.; Sullards, M.C.; Zhu, Q.Y.; Schramm, D.D.; Hammerstone, J.F.; Fraga, C.G.; 
Schmitz, H.H.; Keen, C.L. Procyanidin dimer B2 [epicatechin-(4β-8)-epicatechin] in human 
plasma after the consumption of a flavanol-rich cocoa. Am. J. Clin. Nutr. 2002, 76, 798–804. 
95. Richelle, M.; Tavazzi, I.; Enslen, M.; Offord, E.A. Plasma kinetics in man of epicatechin from 
black chocolate. Eur. J. Clin. Nutr. 1999, 53, 22–26. 
96. Mullen, W.; Borges, G.; Donovan, J.L.; Edwards, C.A.; Serafini, M.; Lean, M.E.; Crozier, A. 
Milk decreases urinary excretion but not plasma pharmacokinetics of cocoa flavan-3-ol 
metabolites in humans. Am. J. Clin. Nutr. 2009, 89, 1784–1791. 
97. Actis-Goretta, L.; Leveques, A.; Giuffrida, F.; Romanov-Michailidis, F.; Viton, F.; Barron, D.; 
Duenas-Paton, M.; Gonzalez-Manzano, S.; Santos-Buelga, C.; Williamson, G.; et al. Elucidation 
of (−)-epicatechin metabolites after ingestion of chocolate by healthy humans. Free Radic.  
Biol. Med. 2012, 53, 787–795. 
98. Baba, S.; Osakabe, N.; Yasuda, A.; Natsume, M.; Takizawa, T.; Nakamura, T.; Terao, J. 
Bioavailability of (−)-epicatechin upon intake of chocolate and cocoa in human volunteers.  
Free Radic. Res. 2000, 33, 635–641. 
99. Actis-Goretta, L.; Leveques, A.; Rein, M.; Teml, A.; Schafer, C.; Hofmann, U.; Li, H.;  
Schwab, M.; Eichelbaum, M.; Williamson, G. Intestinal absorption, metabolism, and excretion of 
(−)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am. J. 
Clin. Nutr. 2013, 98, 924–933. 
Nutrients 2014, 6 871 
 
 
100. Wang, J.F.; Schramm, D.D.; Holt, R.R.; Ensunsa, J.L.; Fraga, C.G.; Schmitz, H.H.; Keen, C.L.  
A dose-response effect from chocolate consumption on plasma epicatechin and oxidative 
damage. J. Nutr. 2000, 130, 2115S–2119S. 
101. Deprez, S.; Mila, I.; Huneau, J.F.; Tome, D.; Scalbert, A. Transport of proanthocyanidin dimer, 
trimer, and polymer across monolayers of human intestinal epithelial Caco-2 cells.  
Antioxid. Redox Signal. 2001, 3, 957–967. 
102. Spencer, J.P.; Schroeter, H.; Shenoy, B.; Srai, S.K.; Debnam, E.S.; Rice-Evans, C. Epicatechin is 
the primary bioavailable form of the procyanidin dimers B2 and B5 after transfer across the small 
intestine. Biochem. Biophys. Res. Commun. 2001, 285, 588–593. 
103. Ottaviani, J.I.; Momma, T.Y.; Heiss, C.; Kwik-Uribe, C.; Schroeter, H.; Keen, C.L. The 
stereochemical configuration of flavanols influences the level and metabolism of flavanols in 
humans and their biological activity in vivo. Free Radic. Biol. Med. 2011, 50, 237–244. 
104. Ritter, C.; Zimmermann, B.F.; Galensa, R. Chiral separation of (+)/(−)-catechin from sulfated and 
glucuronidated metabolites in human plasma after cocoa consumption. Anal. Bioanal. Chem. 2010, 
397, 723–730. 
105. Rios, L.Y.; Bennett, R.N.; Lazarus, S.A.; Remesy, C.; Scalbert, A.; Williamson, G. Cocoa 
procyanidins are stable during gastric transit in humans. Am. J. Clin. Nutr. 2002, 76, 1106–1110. 
106. Monagas, M.; Urpi-Sarda, M.; Sanchez-Patan, F.; Llorach, R.; Garrido, I.; Gomez-Cordoves, C.; 
Andres-Lacueva, C.; Bartolome, B. Insights into the metabolism and microbial biotransformation 
of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct. 2010, 1, 233–253. 
107. Donovan, J.L.; Manach, C.; Faulks, R.M.; Kroon, P.A. Absorption and Metabolism of Plant 
Secondary Metabolites. In Plant Secondary Metabolites: Occurrence, Structure and Role in the 
Human Diet; Crozier, A., Clifford, M.N., Ashihara, H., Eds.; Blackwell Publishing: Oxford, UK, 
2006; pp. 303–351. 
108. Ottaviani, J.I.; Momma, T.Y.; Kuhnle, G.K.; Keen, C.L.; Schroeter, H. Structurally related  
(−)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized 
authentic standards. Free Radic. Biol. Med. 2012, 52, 1403–1412. 
109. Fogliano, V.; Corollaro, M.L.; Vitaglione, P.; Napolitano, A.; Ferracane, R.; Travaglia, F.; 
Arlorio, M.; Costabile, A.; Klinder, A.; Gibson, G. In vitro bioaccessibility and gut 
biotransformation of polyphenols present in the water-insoluble cocoa fraction. Mol. Nutr.  
Food Res. 2011, 55, S44–S55. 
110. Stoupi, S.; Williamson, G.; Drynan, J.W.; Barron, D.; Clifford, M.N. A comparison of the  
in vitro biotransformation of (−)-epicatechin and procyanidin B2 by human faecal microbiota.  
Mol. Nutr. Food Res. 2010, 54, 747–759. 
111. Rios, L.Y.; Gonthier, M.P.; Remesy, C.; Mila, I.; Lapierre, C.; Lazarus, S.A.; Williamson, G.; 
Scalbert, A. Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in 
healthy human subjects. Am. J. Clin. Nutr. 2003, 77, 912–918. 
112. Meng, X.; Sang, S.; Zhu, N.; Lu, H.; Sheng, S.; Lee, M.J.; Ho, C.T.; Yang, C.S. Identification 
and characterization of methylated and ring-fission metabolites of tea catechins formed in 
humans, mice, and rats. Chem. Res. Toxicol. 2002, 15, 1042–1050. 
  
Nutrients 2014, 6 872 
 
 
113. Urpi-Sarda, M.; Llorach, R.; Khan, N.; Monagas, M.; Rotches-Ribalta, M.; Lamuela-Raventos, R.; 
Estruch, R.; Tinahones, F.J.; Andres-Lacueva, C. Effect of milk on the urinary excretion of 
microbial phenolic acids after cocoa powder consumption in humans. J. Agric. Food Chem. 
2010, 58, 4706–4711. 
114. Urpi-Sarda, M.; Monagas, M.; Khan, N.; Llorach, R.; Lamuela-Raventos, R.M.; Jauregui, O.; 
Estruch, R.; Izquierdo-Pulido, M.; Andres-Lacueva, C. Targeted metabolic profiling of phenolics 
in urine and plasma after regular consumption of cocoa by liquid chromatography-tandem mass 
spectrometry. J. Chromatogr. A 2009, 1216, 7258–7267. 
115. Appeldoorn, M.M.; Vincken, J.P.; Aura, A.M.; Hollman, P.C.; Gruppen, H. Procyanidin  
dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and  
5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. J. Agric. Food Chem. 
2009, 57, 1084–1092. 
116. Urpi-Sarda, M.; Monagas, M.; Khan, N.; Lamuela-Raventos, R.M.; Santos-Buelga, C.; 
Sacanella, E.; Castell, M.; Permanyer, J.; Andres-Lacueva, C. Epicatechin, procyanidins, and 
phenolic microbial metabolites after cocoa intake in humans and rats. Anal. Bioanal. Chem. 
2009, 394, 1545–1556. 
117. Depeint, F.; Gee, J.M.; Williamson, G.; Johnson, I.T. Evidence for consistent patterns between 
flavonoid structures and cellular activities. Proc. Nutr. Soc. 2002, 61, 97–103. 
118. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J. Nutr. 2000, 
130, 2073S–2085S. 
119. Llorach, R.; Urpi-Sarda, M.; Tulipani, S.; Garcia-Aloy, M.; Monagas, M.; Andres-Lacueva, C. 
Metabolomic fingerprint in patients at high risk of cardiovascular disease by cocoa intervention. 
Mol. Nutr. Food Res. 2013, 57, 962–973. 
120. Llorach-Asuncion, R.; Jauregui, O.; Urpi-Sarda, M.; Andres-Lacueva, C. Methodological aspects 
for metabolome visualization and characterization: A metabolomic evaluation of the 24 h 
evolution of human urine after cocoa powder consumption. J. Pharm. Biomed. Anal. 2010, 51, 
373–381. 
121. Llorach, R.; Urpi-Sarda, M.; Jauregui, O.; Monagas, M.; Andres-Lacueva, C. An LC-MS-based 
metabolomics approach for exploring urinary metabolome modifications after cocoa consumption. 
J. Proteome Res. 2009, 8, 5060–5068. 
122. Ito, H.; Gonthier, M.P.; Manach, C.; Morand, C.; Mennen, L.; Remesy, C.; Scalbert, A. 
Polyphenol levels in human urine after intake of six different polyphenol-rich beverages. Br. J. Nutr. 
2005, 94, 500–509. 
123. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Casas, R.; Urpi-Sarda, M.; Llorach, R.;  
Lamuela-Raventos, R.M.; Estruch, R. Effect of cocoa powder on the modulation of inflammatory 
biomarkers in patients at high risk of cardiovascular disease. Am. J. Clin. Nutr. 2009, 90,  
1144–1150. 
124. Khan, N.; Monagas, M.; Andres-Lacueva, C.; Casas, R.; Urpi-Sarda, M.; Lamuela-Raventos, R.M.; 
Estruch, R. Regular consumption of cocoa powder with milk increases HDL cholesterol and 
reduces oxidized LDL levels in subjects at high-risk of cardiovascular disease. Nutr. Metab. 
Cardiovasc. Dis. 2012, 22, 1046–1053. 
Nutrients 2014, 6 873 
 
 
125. Selma, M.V.; Espin, J.C.; Tomas-Barberan, F.A. Interaction between phenolics and gut 
microbiota: Role in human health. J. Agric. Food Chem. 2009, 57, 6485–6501. 
126. Williamson, G.; Clifford, M.N. Colonic metabolites of berry polyphenols: The missing link to 
biological activity? Br. J. Nutr. 2010, 104, S48–S66. 
127. Van Duynhoven, J.; Vaughan, E.E.; Jacobs, D.M.; Kemperman, R.A.; van Velzen, E.J.; Gross, G.; 
Roger, L.C.; Possemiers, S.; Smilde, A.K.; Dore, J.; et al. Metabolic fate of polyphenols in the 
human superorganism. Proc. Natl. Acad. Sci. USA 2011, 108, 4531–4538. 
128. Dall’Asta, M.; Calani, L.; Tedeschi, M.; Jechiu, L.; Brighenti, F.; Del Rio, D. Identification of 
microbial metabolites derived from in vitro fecal fermentation of different polyphenolic food 
sources. Nutrition 2012, 28, 197–203. 
129. Prakash, S.; Rodes, L.; Coussa-Charley, M.; Tomaro-Duchesneau, C. Gut microbiota: Next 
frontier in understanding human health and development of biotherapeutics. Biol. Targets Ther. 
2011, 5, 71–86. 
130. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on 
human health: An integrative view. Cell 2012, 148, 1258–1270. 
131. Flint, H.J.; Scott, K.P.; Louis, P.; Duncan, S.H. The role of the gut microbiota in nutrition and 
health. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 577–589. 
132. Lozupone, C.A.; Stombaugh, J.I.; Gordon, J.I.; Jansson, J.K.; Knight, R. Diversity, stability and 
resilience of the human gut microbiota. Nature 2012, 489, 220–230. 
133. Cardona, F.; Andres-Lacueva, C.; Tulipani, S.; Tinahones, F.J.; Queipo-Ortuno, M.I. Benefits of 
polyphenols on gut microbiota and implications in human health. J. Nutr. Biochem. 2013, 24, 
1415–1422. 
134. Bolca, S.; van de Wiele, T.; Possemiers, S. Gut metabotypes govern health effects of dietary 
polyphenols. Curr. Opin. Biotechnol. 2013, 24, 220–225. 
135. Martin, F.P.; Montoliu, I.; Nagy, K.; Moco, S.; Collino, S.; Guy, P.; Redeuil, K.; Scherer, M.; 
Rezzi, S.; Kochhar, S. Specific dietary preferences are linked to differing gut microbial metabolic 
activity in response to dark chocolate intake. J. Proteome Res. 2012, 11, 6252–6263. 
136. Serafini, M.; Bugianesi, R.; Maiani, G.; Valtuena, S.; de Santis, S.; Crozier, A. Plasma 
antioxidants from chocolate. Nature 2003, 424, 1013. 
137. Roura, E.; Andres-Lacueva, C.; Estruch, R.; Lourdes Mata Bilbao, M.; Izquierdo-Pulido, M.; 
Lamuela-Raventos, R.M. The effects of milk as a food matrix for polyphenols on the excretion 
profile of cocoa (−)-epicatechin metabolites in healthy human subjects. Br. J. Nutr. 2008, 100, 
846–851. 
138. Roura, E.; Andres-Lacueva, C.; Estruch, R.; Mata-Bilbao, M.L.; Izquierdo-Pulido, M.; 
Waterhouse, A.L.; Lamuela-Raventos, R.M. Milk does not affect the bioavailability of cocoa 
powder flavonoid in healthy human. Ann. Nutr. Metab. 2007, 51, 493–498. 
139. Schroeter, H.; Holt, R.R.; Orozco, T.J.; Schmitz, H.H.; Keen, C.L. Nutrition: Milk and 
absorption of dietary flavanols. Nature 2003, 426, 787–788. 
140. Keogh, J.B.; McInerney, J.; Clifton, P.M. The effect of milk protein on the bioavailability of 
cocoa polyphenols. J. Food Sci. 2007, 72, S230–S233. 
Nutrients 2014, 6 874 
 
 
141. Schramm, D.D.; Karim, M.; Schrader, H.R.; Holt, R.R.; Kirkpatrick, N.J.; Polagruto, J.A.; 
Ensunsa, J.L.; Schmitz, H.H.; Keen, C.L. Food effects on the absorption and pharmacokinetics of 
cocoa flavanols. Life Sci. 2003, 73, 857–869. 
142. Rodriguez-Mateos, A.; Oruna-Concha, M.J.; Kwik-Uribe, C.; Vidal, A.; Spencer, J.P. Influence 
of sugar type on the bioavailability of cocoa flavanols. Br. J. Nutr. 2012, 108, 2243–2250. 
143. Ferruzzi, M.G.; Bordenave, N.; Hamaker, B.R. Does flavor impact function? Potential 
consequences of polyphenol-protein interactions in delivery and bioactivity of flavan-3-ols from 
foods. Physiol. Behav. 2012, 107, 591–597. 
144. Neilson, A.P.; Ferruzzi, M.G. Influence of formulation and processing on absorption and 
metabolism of flavan-3-ols from tea and cocoa. Annu. Rev. Food Sci. Technol. 2011, 2, 125–151. 
145. Neilson, A.P.; George, J.C.; Janle, E.M.; Mattes, R.D.; Rudolph, R.; Matusheski, N.V.;  
Ferruzzi, M.G. Influence of chocolate matrix composition on cocoa flavan-3-ol bioaccessibility 
in vitro and bioavailability in humans. J. Agric. Food Chem. 2009, 57, 9418–9426. 
146. Wan, Y.; Vinson, J.A.; Etherton, T.D.; Proch, J.; Lazarus, S.A.; Kris-Etherton, P.M. Effects of 
cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations 
in humans. Am. J. Clin. Nutr. 2001, 74, 596–602. 
147. Rimbach, G.; Egert, S.; de Pascual-Teresa, S. Chocolate: (Un)healthy source of polyphenols? 
Genes Nutr. 2011, 6, 1–3. 
148. Murphy, K.J.; Chronopoulos, A.K.; Singh, I.; Francis, M.A.; Moriarty, H.; Pike, M.J.;  
Turner, A.H.; Mann, N.J.; Sinclair, A.J. Dietary flavanols and procyanidin oligomers from cocoa 
(Theobroma cacao) inhibit platelet function. Am. J. Clin. Nutr. 2003, 77, 1466–1473. 
149. Martin, F.P.; Rezzi, S.; Pere-Trepat, E.; Kamlage, B.; Collino, S.; Leibold, E.; Kastler, J.;  
Rein, D.; Fay, L.B.; Kochhar, S. Metabolic effects of dark chocolate consumption on energy, gut 
microbiota, and stress-related metabolism in free-living subjects. J. Proteome Res. 2009, 8, 
5568–5579. 
150. Rice-Evans, C. Flavonoid antioxidants. Curr. Med. Chem. 2001, 8, 797–807. 
151. Kris-Etherton, P.M.; Keen, C.L. Evidence that the antioxidant flavonoids in tea and cocoa are 
beneficial for cardiovascular health. Curr. Opin. Lipidol. 2002, 13, 41–49. 
152. McCullough, M.L.; Chevaux, K.; Jackson, L.; Preston, M.; Martinez, G.; Schmitz, H.H.; Coletti, C.; 
Campos, H.; Hollenberg, N.K. Hypertension, the Kuna, and the epidemiology of flavanols.  
J. Cardiovasc. Pharmacol. 2006, 47, S103–S109. 
153. Mink, P.J.; Scrafford, C.G.; Barraj, L.M.; Harnack, L.; Hong, C.P.; Nettleton, J.A.; Jacobs, D.R., Jr. 
Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal 
women. Am. J. Clin. Nutr. 2007, 85, 895–909. 
154. Baba, S.; Osakabe, N.; Kato, Y.; Natsume, M.; Yasuda, A.; Kido, T.; Fukuda, K.; Muto, Y.; 
Kondo, K. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL 
oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in 
humans. Am. J. Clin. Nutr. 2007, 85, 709–717. 
155. Osakabe, N.; Baba, S.; Yasuda, A.; Iwamoto, T.; Kamiyama, M.; Takizawa, T.; Itakura, H.; 
Kondo, K. Daily cocoa intake reduces the susceptibility of low-density lipoprotein to oxidation 
as demonstrated in healthy human volunteers. Free Radic. Res. 2001, 34, 93–99. 
Nutrients 2014, 6 875 
 
 
156. Sarria, B.; Martinez-Lopez, S.; Sierra-Cinos, J.L.; Garcia-Diz, L.; Mateos, R.; Bravo, L. Regular 
consumption of a cocoa product improves the cardiometabolic profile in healthy and moderately 
hypercholesterolaemic adults. Br. J. Nutr. 2014, 111, 122–134. 
157. Fisher, N.D.; Hollenberg, N.K. Aging and vascular responses to flavanol-rich cocoa. J. Hypertens. 
2006, 24, 1575–1580. 
158. Heiss, C.; Finis, D.; Kleinbongard, P.; Hoffmann, A.; Rassaf, T.; Kelm, M.; Sies, H. Sustained 
increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week.  
J. Cardiovasc. Pharmacol. 2007, 49, 74–80. 
159. Heiss, C.; Kleinbongard, P.; Dejam, A.; Perre, S.; Schroeter, H.; Sies, H.; Kelm, M. Acute 
consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers.  
J. Am. Coll. Cardiol. 2005, 46, 1276–1283. 
160. Innes, A.J.; Kennedy, G.; McLaren, M.; Bancroft, A.J.; Belch, J.J. Dark chocolate inhibits 
platelet aggregation in healthy volunteers. Platelets 2003, 14, 325–327. 
161. Balzer, J.; Rassaf, T.; Heiss, C.; Kleinbongard, P.; Lauer, T.; Merx, M.; Heussen, N.;  
Gross, H.B.; Keen, C.L.; Schroeter, H.; et al. Sustained benefits in vascular function through 
flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, 
controlled trial. J. Am. Coll. Cardiol. 2008, 51, 2141–2149. 
162. Faridi, Z.; Njike, V.Y.; Dutta, S.; Ali, A.; Katz, D.L. Acute dark chocolate and cocoa ingestion 
and endothelial function: A randomized controlled crossover trial. Am. J. Clin. Nutr. 2008, 88, 
58–63. 
163. Lichtenstein, A.H.; Appel, L.J.; Brands, M.; Carnethon, M.; Daniels, S.; Franch, H.A.;  
Franklin, B.; Kris-Etherton, P.; Harris, W.S.; Howard, B.; et al. Summary of American heart 
association diet and lifestyle recommendations revision 2006. Arterioscler. Thromb. Vasc. Biol. 
2006, 26, 2186–2191. 
164. Baba, S.; Natsume, M.; Yasuda, A.; Nakamura, Y.; Tamura, T.; Osakabe, N.; Kanegae, M.; 
Kondo, K. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in 
normo- and hypercholesterolemic humans after intake of different levels of cocoa powder.  
J. Nutr. 2007, 137, 1436–1441. 
165. Mursu, J.; Voutilainen, S.; Nurmi, T.; Rissanen, T.H.; Virtanen, J.K.; Kaikkonen, J.; Nyyssonen, K.; 
Salonen, J.T. Dark chocolate consumption increases HDL cholesterol concentration and 
chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic. Biol. Med. 
2004, 37, 1351–1359. 
166. Di Renzo, L.; Rizzo, M.; Sarlo, F.; Colica, C.; Iacopino, L.; Domino, E.; Sergi, D.; de Lorenzo, A. 
Effects of dark chocolate in a population of Normal Weight Obese women: A pilot study.  
Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 2257–2266. 
167. Steinberg, D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 
1997, 272, 20963–20966. 
168. Witztum, J.L.; Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis.  
J. Clin. Investig. 1991, 88, 1785–1792. 
169. Fraley, A.E.; Tsimikas, S. Clinical applications of circulating oxidized low-density lipoprotein 
biomarkers in cardiovascular disease. Curr. Opin. Lipidol. 2006, 17, 502–509. 
Nutrients 2014, 6 876 
 
 
170. Holvoet, P.; Lee, D.H.; Steffes, M.; Gross, M.; Jacobs, D.R., Jr. Association between circulating 
oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 2008, 299, 
2287–2293. 
171. Ishigaki, Y.; Oka, Y.; Katagiri, H. Circulating oxidized LDL: A biomarker and a pathogenic 
factor. Curr. Opin. Lipidol. 2009, 20, 363–369. 
172. Osakabe, N.; Yasuda, A.; Natsume, M.; Takizawa, T.; Terao, J.; Kondo, K. Catechins and their 
oligomers linked by C4→C8 bonds are major cacao polyphenols and protect low-density 
lipoprotein from oxidation in vitro. Exp. Biol. Med. 2002, 227, 51–56. 
173. Richelle, M.; Tavazzi, I.; Offord, E. Comparison of the antioxidant activity of commonly 
consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J. Agric. 
Food Chem. 2001, 49, 3438–3442. 
174. Kurosawa, T.; Itoh, F.; Nozaki, A.; Nakano, Y.; Katsuda, S.; Osakabe, N.; Tsubone, H.;  
Kondo, K.; Itakura, H. Suppressive effects of cacao liquor polyphenols (CLP) on LDL oxidation 
and the development of atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits. 
Atherosclerosis 2005, 179, 237–246. 
175. Kurosawa, T.; Itoh, F.; Nozaki, A.; Nakano, Y.; Katsuda, S.; Osakabe, N.; Tsubone, H.;  
Kondo, K.; Itakura, H. Suppressive effect of cocoa powder on atherosclerosis in Kurosawa and 
Kusanagi-hypercholesterolemic rabbits. J. Atheroscler. Thromb. 2005, 12, 20–28. 
176. Mathur, S.; Devaraj, S.; Grundy, S.M.; Jialal, I. Cocoa products decrease low density lipoprotein 
oxidative susceptibility but do not affect biomarkers of inflammation in humans. J. Nutr. 2002, 
132, 3663–3667. 
177. Vita, J.A. Endothelial function and clinical outcome. Heart 2005, 91, 1278–1279. 
178. Rein, D.; Paglieroni, T.G.; Wun, T.; Pearson, D.A.; Schmitz, H.H.; Gosselin, R.; Keen, C.L. 
Cocoa inhibits platelet activation and function. Am. J. Clin. Nutr. 2000, 72, 30–35. 
179. Monahan, K.D. Effect of cocoa/chocolate ingestion on brachial artery flow-mediated dilation and 
its relevance to cardiovascular health and disease in humans. Arch. Biochem. Biophys. 2012, 527, 
90–94. 
180. Sies, H.; Schewe, T.; Heiss, C.; Kelm, M. Cocoa polyphenols and inflammatory mediators.  
Am. J. Clin. Nutr. 2005, 81, 304S–312S. 
181. Fisher, N.D.; Hughes, M.; Gerhard-Herman, M.; Hollenberg, N.K. Flavanol-rich cocoa induces 
nitric-oxide-dependent vasodilation in healthy humans. J. Hypertens. 2003, 21, 2281–2286. 
182. Heiss, C.; Dejam, A.; Kleinbongard, P.; Schewe, T.; Sies, H.; Kelm, M. Vascular effects of cocoa 
rich in flavan-3-ols. JAMA 2003, 290, 1030–1031. 
183. Grassi, D.; Necozione, S.; Lippi, C.; Croce, G.; Valeri, L.; Pasqualetti, P.; Desideri, G.; 
Blumberg, J.B.; Ferri, C. Cocoa reduces blood pressure and insulin resistance and improves 
endothelium-dependent vasodilation in hypertensives. Hypertension 2005, 46, 398–405. 
184. Fraga, C.G. Cocoa, diabetes, and hypertension: Should we eat more chocolate? Am. J. Clin. Nutr. 
2005, 81, 541–542. 
185. Flammer, A.J.; Hermann, F.; Sudano, I.; Spieker, L.; Hermann, M.; Cooper, K.A.; Serafini, M.; 
Luscher, T.F.; Ruschitzka, F.; Noll, G.; et al. Dark chocolate improves coronary vasomotion and 
reduces platelet reactivity. Circulation 2007, 116, 2376–2382. 
Nutrients 2014, 6 877 
 
 
186. Holt, R.R.; Actis-Goretta, L.; Momma, T.Y.; Keen, C.L. Dietary flavanols and platelet reactivity. 
J. Cardiovasc. Pharmacol. 2006, 47, S187–S196. 
187. Ross, R. Atherosclerosis—An inflammatory disease. N. Engl. J. Med. 1999, 340, 115–126. 
188. Pearson, T.A.; Mensah, G.A.; Alexander, R.W.; Anderson, J.L.; Cannon, R.O., 3rd; Criqui, M.; 
Fadl, Y.Y.; Fortmann, S.P.; Hong, Y.; Myers, G.L.; et al. Markers of inflammation and 
cardiovascular disease: Application to clinical and public health practice: A statement for 
healthcare professionals from the Centers for Disease Control and Prevention and the American 
Heart Association. Circulation 2003, 107, 499–511. 
189. Tracy, R.P. Inflammation in cardiovascular disease: Cart, horse, or both? Circulation 1998, 97, 
2000–2002. 
190. Libby, P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006, 83, 
456S–460S. 
191. Di Giuseppe, R.; di Castelnuovo, A.; Centritto, F.; Zito, F.; de Curtis, A.; Costanzo, S.; Vohnout, B.; 
Sieri, S.; Krogh, V.; Donati, M.B.; et al. Regular consumption of dark chocolate is associated 
with low serum concentrations of C-reactive protein in a healthy Italian population. J. Nutr. 
2008, 138, 1939–1945. 
192. Abraham, J.; Campbell, C.Y.; Cheema, A.; Gluckman, T.J.; Blumenthal, R.S.; Danyi, P. C-reactive 
protein in cardiovascular risk assessment: A review of the evidence. J. Cardiometab. Syndr. 
2007, 2, 119–123. 
193. Kurlandsky, S.B.; Stote, K.S. Cardioprotective effects of chocolate and almond consumption in 
healthy women. Nutr. Res. 2006, 26, 509–516. 
194. Tzounis, X.; Rodriguez-Mateos, A.; Vulevic, J.; Gibson, G.R.; Kwik-Uribe, C.; Spencer, J.P. 
Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, 
controlled, double-blind, crossover intervention study. Am. J. Clin. Nutr. 2011, 93, 62–72. 
195. Stote, K.S.; Clevidence, B.A.; Novotny, J.A.; Henderson, T.; Radecki, S.V.; Baer, D.J. Effect of 
cocoa and green tea on biomarkers of glucose regulation, oxidative stress, inflammation and 
hemostasis in obese adults at risk for insulin resistance. Eur. J. Clin. Nutr. 2012, 66, 1153–1159. 
196. Hamed, M.S.; Gambert, S.; Bliden, K.P.; Bailon, O.; Singla, A.; Antonino, M.J.; Hamed, F.; 
Tantry, U.S.; Gurbel, P.A. Dark chocolate effect on platelet activity, C-reactive protein and lipid 
profile: A pilot study. South. Med. J. 2008, 101, 1203–1208. 
197. Schisterman, E.F.; Mumford, S.L.; Sjaarda, L.A. Failure to consider the menstrual cycle phase 
may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in 
premenopausal women. Epidemiol. Rev. 2014, 36, 71–82. 
198. Farouque, H.M.; Leung, M.; Hope, S.A.; Baldi, M.; Schechter, C.; Cameron, J.D.; Meredith, I.T. 
Acute and chronic effects of flavanol-rich cocoa on vascular function in subjects with coronary 
artery disease: A randomized double-blind placebo-controlled study. Clin. Sci. 2006, 111, 71–80. 
199. Grassi, D.; Desideri, G.; Necozione, S.; Lippi, C.; Casale, R.; Properzi, G.; Blumberg, J.B.;  
Ferri, C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, 
hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J. Nutr. 2008, 
138, 1671–1676. 
  
Nutrients 2014, 6 878 
 
 
200. Wang-Polagruto, J.F.; Villablanca, A.C.; Polagruto, J.A.; Lee, L.; Holt, R.R.; Schrader, H.R.; 
Ensunsa, J.L.; Steinberg, F.M.; Schmitz, H.H.; Keen, C.L. Chronic consumption of flavanol-rich 
cocoa improves endothelial function and decreases vascular cell adhesion molecule in 
hypercholesterolemic postmenopausal women. J. Cardiovasc. Pharmacol. 2006, 47, S177–S186. 
201. Muniyappa, R.; Hall, G.; Kolodziej, T.L.; Karne, R.J.; Crandon, S.K.; Quon, M.J. Cocoa 
consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood 
pressure or insulin resistance in essential hypertension. Am. J. Clin. Nutr. 2008, 88, 1685–1696. 
202. Nogueira Lde, P.; Knibel, M.P.; Torres, M.R.; Nogueira Neto, J.F.; Sanjuliani, A.F. Consumption 
of high-polyphenol dark chocolate improves endothelial function in individuals with stage 1 
hypertension and excess body weight. Int. J. Hypertens. 2012, 2012, 147321. 
203. Vazquez-Agell, M.; Urpi-Sarda, M.; Sacanella, E.; Camino-Lopez, S.; Chiva-Blanch, G.; 
Llorente-Cortes, V.; Tobias, E.; Roura, E.; Andres-Lacueva, C.; Lamuela-Raventos, R.M.; et al. 
Cocoa consumption reduces NF-κB activation in peripheral blood mononuclear cells in humans. 
Nutr. Metab. Cardiovasc. Dis. 2013, 23, 257–263. 
204. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma 
concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial 
infarction in apparently healthy men. Lancet 1998, 351, 88–92. 
205. Blann, A.D.; Seigneur, M.; Steiner, M.; Miller, J.P.; McCollum, C.N. Circulating ICAM-1 and 
VCAM-1 in peripheral artery disease and hypercholesterolaemia: Relationship to the location of 
atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb. Haemost. 
1998, 79, 1080–1085. 
206. Von der Thüsen, J.H.; Kuiper, J.; van Berkel, T.J.C.; Biessen, E.A.L. Interleukins in atherosclerosis: 
Molecular pathways and therapeutic potential. Pharmacol. Rev. 2003, 55, 133–166. 
207. Thurberg, B.L.; Collins, T. The nuclear factor-κB/inhibitor of kappa B autoregulatory system and 
atherosclerosis. Curr. Opin. Lipidol. 1998, 9, 387–396. 
208. Funk, C.D. Leukotriene inflammatory mediators meet their match. Sci. Transl. Med. 2011,  
3, 66ps3. 
209. Riccioni, G.; Back, M. Leukotrienes as modifiers of preclinical atherosclerosis? Sci. World J. 
2012, 2012, 490968. 
210. Gu, Y.; Yu, S.; Lambert, J.D. Dietary cocoa ameliorates obesity-related inflammation in high  
fat-fed mice. Eur. J. Nutr. 2014, 53, 149–158. 
211. Vinson, J.A.; Proch, J.; Bose, P.; Muchler, S.; Taffera, P.; Shuta, D.; Samman, N.; Agbor, G.A. 
Chocolate is a powerful ex vivo and in vivo antioxidant, an antiatherosclerotic agent in an animal 
model, and a significant contributor to antioxidants in the European and American Diets.  
J. Agric. Food Chem. 2006, 54, 8071–8076. 
212. Desch, S.; Schmidt, J.; Kobler, D.; Sonnabend, M.; Eitel, I.; Sareban, M.; Rahimi, K.; Schuler, G.; 
Thiele, H. Effect of cocoa products on blood pressure: Systematic review and meta-analysis.  
Am. J. Hypertens. 2010, 23, 97–103. 
213. Yakala, G.K.; Wielinga, P.Y.; Suarez, M.; Bunschoten, A.; van Golde, J.M.; Arola, L.; Keijer, J.; 
Kleemann, R.; Kooistra, T.; Heeringa, P. Effects of chocolate supplementation on metabolic and 
cardiovascular parameters in ApoE3L mice fed a high-cholesterol atherogenic diet. Mol. Nutr. 
Food Res. 2013, 57, 2039–2048. 
Nutrients 2014, 6 879 
 
 
214. Ramos-Romero, S.; Pérez-Cano, F.J.; Pérez-Berezo, T.; Castellote, C.; Franch, A.; Catell, M.  
A seven-day high cocoa diet decreces oxidant and inflammatory properties of peritoneal 
macrophages in rats. Proc. Nutr. Soc. 2010, 69, E253. 
215. Schewe, T.; Sadik, C.; Klotz, L.O.; Yoshimoto, T.; Kuhn, H.; Sies, H. Polyphenols of cocoa: 
Inhibition of mammalian 15-lipoxygenase. Biol. Chem. 2001, 382, 1687–1696. 
216. Schewe, T.; Kuhn, H.; Sies, H. Flavonoids of cocoa inhibit recombinant human 5-lipoxygenase. 
J. Nutr. 2002, 132, 1825–1829. 
217. Mao, T.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Cocoa procyanidins and 
human cytokine transcription and secretion. J. Nutr. 2000, 130, 2093S–2099S. 
218. Mao, T.K.; Powell, J.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Hammerstone, J.F.; 
Gershwin, M.E. The effect of cocoa procyanidins on the transcription and secretion of interleukin 
1 beta in peripheral blood mononuclear cells. Life Sci. 2000, 66, 1377–1386. 
219. Mao, T.K.; Powell, J.; van de water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Effect of 
cocoa procyanidins on the secretion of interleukin-4 in peripheral blood mononuclear cells.  
J. Med. Food 2000, 3, 107–114. 
220. Mao, T.K.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Modulation of  
TNF-alpha secretion in peripheral blood mononuclear cells by cocoa flavanols and procyanidins. 
Dev. Immunol. 2002, 9, 135–141. 
221. Mao, T.K.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Effect of cocoa 
flavanols and their related oligomers on the secretion of interleukin-5 in peripheral blood 
mononuclear cells. J. Med. Food 2002, 5, 17–22. 
222. Ramiro, E.; Franch, A.; Castellote, C.; Perez-Cano, F.; Permanyer, J.; Izquierdo-Pulido, M.; 
Castell, M. Flavonoids from Theobroma cacao down-regulate inflammatory mediators. J. Agric. 
Food Chem. 2005, 53, 8506–8511. 
223. Ramiro, E.; Franch, A.; Castellote, C.; Andres-Lacueva, C.; Izquierdo-Pulido, M.; Castell, M. 
Effect of Theobroma cacao flavonoids on immune activation of a lymphoid cell line. Br. J. Nutr. 
2005, 93, 859–866. 
224. Kenny, T.P.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Immune effects of cocoa procyanidin 
oligomers on peripheral blood mononuclear cells. Exp. Biol. Med. 2007, 232, 293–300. 
225. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Urpi-Sarda, M.; Vazquez-Agell, M.;  
Lamuela-Raventos, R.M.; Estruch, R. Dihydroxylated phenolic acids derived from microbial 
metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood 
mononuclear cells. Br. J. Nutr. 2009, 102, 201–206. 
226. Mackenzie, G.G.; Carrasquedo, F.; Delfino, J.M.; Keen, C.L.; Fraga, C.G.; Oteiza, P.I. 
Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-κB activation at 
multiple steps in Jurkat T cells. FASEB J. 2004, 18, 167–169. 
227. Kroon, P.A.; Clifford, M.N.; Crozier, A.; Day, A.J.; Donovan, J.L.; Manach, C.; Williamson, G. 
How should we assess the effects of exposure to dietary polyphenols in vitro? Am. J. Clin. Nutr. 
2004, 80, 15–21. 
228. Saliou, C.; Valacchi, G.; Rimbach, G. Assessing bioflavonoids as regulators of NF-κB activity 
and inflammatory gene expression in mammalian cells. Methods Enzymol. 2001, 335, 380–387. 
Nutrients 2014, 6 880 
 
 
229. Park, Y.C.; Rimbach, G.; Saliou, C.; Valacchi, G.; Packer, L. Activity of monomeric, dimeric, 
and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-κB-dependent gene 
expression in RAW 264.7 macrophages. FEBS Lett. 2000, 465, 93–97. 
230. Fraga, C.G.; Oteiza, P.I. Dietary flavonoids: Role of (−)-epicatechin and related procyanidins in 
cell signaling. Free Radic. Biol. Med. 2011, 51, 813–823. 
231. Patel, K.R.; Andreadi, C.; Britton, R.G.; Horner-Glister, E.; Karmokar, A.; Sale, S.; Brown, V.A.; 
Brenner, D.E.; Singh, R.; Steward, W.P.; et al. Sulfate metabolites provide an intracellular pool 
for resveratrol generation and induce autophagy with senescence. Science Transl. Med. 2013,  
5, 205ra133. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
